US20200123546A1

US20200123546A1 - Antisense nucleic acid for treating amyotrophy

Info

Publication number: US20200123546A1
Application number: US16/722,680
Authority: US
Inventors: Shinichiro Nakagawa
Original assignee: Nippon Shinyaku Co Ltd; Kawasaki Gakuen Educational Foundation
Current assignee: Nippon Shinyaku Co Ltd; Kawasaki Gakuen Educational Foundation
Priority date: 2015-09-16
Filing date: 2019-12-20
Publication date: 2020-04-23
Also published as: TWI726914B; US10563199B2; JP6875684B2; JPWO2017047741A1; EP3351634A1; US20180251760A1; TW201720925A; EP3351634A4; WO2017047741A1

Abstract

There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.

Description

TECHNICAL FIELD

The present invention relates to an antisense oligomer which allows exon 2 skipping in the myostatin gene, and a pharmaceutical composition comprising such an oligomer.

BACKGROUND ART

Myostatin (also known as GDF-8) was discovered in 1997 as a novel cytokine belonging to the TGF-β superfamily. Its expression is specific to skeletal muscle which is a primary tissue responsible for movement and metabolism. Myostatin-deficient mutant animals show significant muscle hypertrophy where skeletal muscle mass is increased twice as much as in wild-type animals, so that myostatin is considered to be a negative control factor for skeletal muscle mass.
Based on the above findings, a therapeutic strategy can be designed to treat amyotrophic diseases or muscle wasting diseases through inhibition of myostatin. Skeletal muscle atrophy will induce not only limitation of daily living activities due to muscle weakness, but also serious systemic complications such as undernutrition and respiratory failure. Target diseases of this therapeutic strategy may include myogenic amyotrophy (e.g., muscular dystrophy, congenital myopathy, inclusion body myositis), neurogenic amyotrophy (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy), disuse amyotrophy (e.g., apoplexy-induced disuse syndrome), muscle wasting diseases (e.g., cancer cachexia, sepsis-related amyotrophy), various types of sarcopenia including age-related skeletal muscle loss (age-related sarcopenia), etc.
The human myostatin gene is located on the long arm of chromosome 2. From three exons constituting this gene, mature mRNA having a chain length of approximately 2.8 kilobases is transcribed and further translated into a precursor polypeptide consisting of 375 amino acid residues. Myostatin precursor polypeptide molecules form a dimer through disulfide bonding between their C-terminal domains, and then cleaved between amino acid residues at positions 266 and 267 (R-D) in endoplasmic reticulum by the actin of a protease of the Furin family, so that the precursor dimer is divided into an N-terminal propeptide and a C-terminal domain dimer which will function later as active myostatin. These peptides are associated through non-covalent bonding and secreted as an inactive complex into the extracellular environment. This complex is further dissociated when the N-terminal propeptide is cleaved off between amino acid residues at positions 98 and 99 (R-D) by the action of a matrix metalloprotease of the BMP1/Tolloid family, whereby an active myostatin dimer appears.
In recent years, attention has been focused on antisense nucleic acid drugs, which are designed and chemically synthesized as short antisense artificial nucleic acids binding complementarily to a part of precursor mRNA in an attempt to inhibit mRNA function. In the normal mechanism of gene transcription, introns in precursor mRNA are cleaved and removed by the action of an enzyme complex called spliceosome to thereby generate mature mRNA. An antisense nucleic acid for exon skipping is designed to modify this spliceosome-mediated splicing regulatory mechanism and induce the generation of mRNA different from normal mature mRNA, thereby inhibiting the function of the gene. Moreover, mRNA is associated not only with the spliceosome, but also with an mRNA-stabilizing protein or an expression/translation regulatory factor (including miRNA) for regulation of mRNA degradation, expression and translation. An antisense nucleic acid is also considered to inhibit the association of such an mRNA-binding protein to its target mRNA, thereby inhibiting the function of the gene.
Currently, some antisense nucleic acids have been known to cause exon skipping in myostatin (Patent Documents 1 to 3 and Non-patent Documents 1 to 4).

PRIOR ART DOCUMENTS

Patent Documents

Patent Document 1: US2013/0085139A1
Patent Document 2: WO2006/086667A2
Patent Document 3: JP2007-104971A

Non-patent Documents

Non-patent Document 1: Kang J K et al., Mol. Ther. (2011) 19(1):159-164
Non-patent Document 2: Kemaladewi et al., BMC Med Genomics. (2011) 4:36
Non-patent Document 3: Alberto Malerba et al., Mol. Ther. Nucleic Acids. (2012) 1:e62
Non-patent Document 4: Bestas B et al., Nucleic Acid Ther. (2014) 24(1):13-24

SUMMARY OF THE INVENTION

Problem to be Solved by the Invention

Under such circumstances as described above, there has been a demand for a novel antisense nucleic acid capable of inhibiting myostatin at the mRNA level.

Means to Solve the Problem

As a result of repeating extensive and intensive efforts to solve the problem stated above, the inventors of the present invention have found that myostatin can be efficiently inhibited at the mRNA level when a particular function inhibitory antisense nucleic acid is applied to the myostatin gene. This finding led to the completion of the present invention.
Namely, the present invention is as follows.

[1]

An antisense oligomer of 14 to 30 bases in length comprising the following unit oligomers connected together:

(a) a first unit oligomer comprising a nucleotide sequence complementary to a first nucleotide sequence consisting of contiguous 7 to 15 bases in exon 2 of the human or mouse myostatin gene; and
(b) a second unit oligomer comprising a nucleotide sequence complementary to a second nucleotide sequence consisting of contiguous 7 to 15 bases in said exon 2,

wherein the first nucleotide sequence and the second nucleotide sequence are not contiguous to each other or do not overlap with each other, or a pharmaceutically acceptable salt or hydrate thereof.

[2]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [1] above, wherein the antisense oligomer is (c) or (d) shown below:

(c) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (c-1) to (c-6) shown below:

(c-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene;
(c-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene;
(c-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene;
(c-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 166 to 210 from the 5′ -terminal end of exon 2 in the human myostatin gene;
(c-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene; and
(c-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene; or

(d) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (d-1) to (d-7) shown below:

(d-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions −10 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 196 to 233 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene; and
(d-7) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene.

[3]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [1] above, wherein the antisense oligomer is (e) or (f) shown below:

(e) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (e-1) to (e-6) shown below:

(e-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions -4 to 25 from the 5′-terminal end of exon 2 in the human myostatin gene;
(e-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 112 to 131 from the 5′-terminal end of exon 2 in the human myostatin gene;
(e-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 128 to 142 from the 5′-terminal end of exon 2 in the human myostatin gene;
(e-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 169 to 206 from the 5′-terminal end of exon 2 in the human myostatin gene;
(e-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 209 to 228 from the 5′-terminal end of exon 2 in the human myostatin gene; and
(e-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 331 to 365 from the 5′-terminal end of exon 2 in the human myostatin gene; or

(f) an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of unit oligomers (f-1) to (f-7) shown below:

(f-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 1 to 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 211 to 225 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 271 to 282 from the 5′-terminal end of exon 2 in the mouse myostatin gene; and
(f-7) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene.

[4]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [2] above, wherein the antisense oligomer (c) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 103 (NMS-48), SEQ ID NO: 116 (NMS-89), SEQ ID NO: 117 (NMS-90), SEQ ID NO: 120 (NMS-93), SEQ ID NO: 128 (NMS-101), SEQ ID NO: 131 (NMS-104), SEQ ID NO: 136 (NMS-113), SEQ ID NO: 137 (NMS-117), SEQ ID NO: 140 (NMS-123), SEQ ID NO: 145 (NMS-136), SEQ ID NO: 146 (NMS-139), SEQ ID NO: 147 (NMS-140), SEQ ID NO: 148 (NMS-141), SEQ ID NO: 149 (NMS-142), SEQ ID NO: 152 (NMS-145), SEQ ID NO: 155 (NMS-148), SEQ ID NO: 156 (NMS-149), SEQ ID NO: 157 (NMS-150), SEQ ID NO: 159 (NMS-152), SEQ ID NO: 162 (NMS-156), SEQ ID NO: 163 (NMS-157), SEQ ID NO: 165 (NMS-162), SEQ ID NO: 166 (NMS-163), SEQ ID NO: 167 (NMS-164), SEQ ID NO: 168 (NMS-166), SEQ ID NO: 169 (NMS-167), SEQ ID NO: 170 (NMS-168), SEQ ID NO: 171 (NMS-169), SEQ ID NO: 176 (NMS-174), SEQ ID NO: 177 (NMS-175), SEQ ID NO: 178 (NMS-176), SEQ ID NO: 179 (NMS-177), SEQ ID NO: 180 (NMS-178), SEQ ID NO: 183 (NMS-181), SEQ ID NO: 187 (NMS-185), SEQ ID NO: 189 (NMS-188), SEQ ID NO: 190 (NMS-189), SEQ ID NO: 191 (NMS-190), SEQ ID NO: 192 (NMS-191), SEQ ID NO: 193 (NMS-192), SEQ ID NO: 196 (NMS-195), SEQ ID NO: 199 (NMS-198), SEQ ID NO: 200 (NMS-199), SEQ ID NO: 201 (NMS-200), SEQ ID NO: 203 (NMS-202), SEQ ID NO: 204 (NMS-203), SEQ ID NO: 206 (NMS-206), SEQ ID NO: 208 (NMS-208), SEQ ID NO: 212 (NMS-212), SEQ ID NO: 213 (NMS-213), SEQ ID NO: 214 (NMS-214), SEQ ID NO: 215 (NMS-215), SEQ ID NO: 217 (NMS-217), SEQ ID NO: 225 (NMS-225), SEQ ID NO: 226 (NMS-228), SEQ ID NO: 228 (NMS-230), SEQ ID NO: 229 (NMS-231), SEQ ID NO: 231 (NMS-233), SEQ ID NO: 232 (NMS-234), SEQ ID NO: 233 (NMS-235), SEQ ID NO: 236 (NMS-240), SEQ ID NO: 237 (NMS-241), SEQ ID NO: 240 (NMS-244), SEQ ID NO: 243 (NMS-247), SEQ ID NO: 244 (NMS-248), SEQ ID NO: 245 (NMS-249), SEQ ID NO: 246 (NMS-250), SEQ ID NO: 247 (NMS-251), SEQ ID NO: 248 (NMS-252), SEQ ID NO: 252 (NMS-256), SEQ ID NO: 261 (NMS-272), SEQ ID NO: 273 (NMS-284), SEQ ID NO: 274 (NMS-285), SEQ ID NO: 275 (NMS-286) and SEQ ID NO: 277 (NMS-297).

[5]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [2] above, wherein the antisense oligomer (d) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 95 (NMS-38), SEQ ID NO: 96 (NMS-39), SEQ ID NO: 107 (NMS-66), SEQ ID NO: 223 (NMS-223), SEQ ID NO: 234 (NMS-238), SEQ ID NO: 235 (NMS-239), SEQ ID NO: 242 (NMS-246), SEQ ID NO: 249 (NMS-253), SEQ ID NO: 250 (NMS-254), SEQ ID NO: 251 (NMS-255), SEQ ID NO: 257 (NMS-268), SEQ ID NO: (NMS-280), SEQ ID NO: (NMS-281), SEQ ID NO: (NMS-282), SEQ ID NO: (NMS-288), SEQ ID NO: (NMS-289), SEQ ID NO: (NMS-290), SEQ ID NO: (NMS-292), SEQ ID NO: (NMS-293), SEQ ID NO: (NMS-294), SEQ ID NO: (NMS-295), SEQ ID NO: (NMS-298), SEQ ID NO: (NMS-299), SEQ ID NO: (NMS-300), SEQ ID NO: (NMS-302) and SEQ ID NO: (NMS-303).

[6]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [1] to [5] above, wherein the antisense oligomer is an oligonucleotide.

[7]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [6] above, wherein at least one sugar moiety and/or at least one phosphate bond moiety in nucleotides constituting the oligonucleotide is modified.

[8]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [7] above, wherein the at least one sugar moiety in nucleotides constituting the oligonucleotide is a ribose in which the -OH group at the 2′-position is substituted with any group selected from the group consisting of OR, R, R′OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R represents alkyl or aryl, and R′ represents alkylene).

[9]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [7] or [8] above, wherein the at least one phosphate bond moiety in nucleotides constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoroamidate bond and a boranophosphate bond.

[10]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [1] to [5] above, wherein the antisense oligomer is a morpholino oligomer.

[11]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [10] above, wherein the morpholino oligomer is a phosphorodiamidate morpholino oligomer.

[12]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [10] or [11] above, whose 5′-terminal end is any one of the groups represented by chemical formulae (1) to (3) shown below.

[13]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [4] and [6] to [12] above, wherein the antisense oligomer consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 171 (NMS-169), SEQ ID NO: 192 (NMS-191), SEQ ID NO: 245 (NMS-249) and SEQ ID NO: 231 (NMS-233).

[14]

A pharmaceutical composition comprising the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [3] to [13] above.

[15]

The pharmaceutical composition according to [14] above, which further comprises a pharmaceutically acceptable carrier.

[16]

The pharmaceutical composition according to [14] or [15] above for use in the treatment of an amyotrophic disease or a muscle wasting disease.

[17]

The pharmaceutical composition according to [16] above for use in the treatment of muscular dystrophy.

[18]

A method for prevention or treatment of an amyotrophic disease or a muscle wasting disease, which comprises administering a subject in need of prevention or treatment of an amyotrophic disease or a muscle wasting disease with a therapeutically effective amount of the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [1] to [13] above.

[19]

The method according to [18] above, wherein the amyotrophic disease or muscle wasting disease is muscular dystrophy.

[20]

The method according to [18] or [19] above, wherein the subject is a human subject.

[21]

Use of the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [1] to [13] above in the manufacture of a pharmaceutical composition for treatment of an amyotrophic disease or a muscle wasting disease.

[22]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [1] to [13] above for use in the treatment of an amyotrophic disease or a muscle wasting disease.

[23]

Any one antisense oligomer selected from the group consisting of (A) to (H) shown below or a pharmaceutically acceptable salt or hydrate thereof:

(A) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene;
(B) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene;
(C) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene;
(D) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene;
(E) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(F) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(G) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene; and
(H) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5 ‘-terminal end of exon 2 in the mouse myostatin gene.
[24]

Any one antisense oligomer selected from the group consisting of (I) to (L) shown below or a pharmaceutically acceptable salt or hydrate thereof:

(I) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 31 from the 5’-terminal end of exon 2 in the human myostatin gene;
(J) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene, wherein the 3′-terminal base of the nucleotide sequence of 14 to 30 bases in length is a base located at position 140 from the 5′-terminal end of said exon 2;
(K) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene; and
(L) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene.
[25]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (A) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 13 (NMS-17), SEQ ID NO: 76 (NMS-138), SEQ ID NO: 68 (NMS-120), SEQ ID NO: 75 (NMS-137), SEQ ID NO: 51 (NMS-76), SEQ ID NO: 52 (NMS-79), SEQ ID NO: 54 (NMS-81), SEQ ID NO: 55 (NMS-82), SEQ ID NO: 56 (NMS-83), SEQ ID NO: 53 (NMS-80), SEQ ID NO: 33 (NMS-49), SEQ ID NO: 63 (NMS-114), SEQ ID NO: 69 (NMS-124), SEQ ID NO: 70 (NMS-125), SEQ ID NO: 61 (NMS-110), SEQ ID NO: 31 (NMS-46), SEQ ID NO: 34 (NMS-50), SEQ ID NO: 50 (NMS-75), SEQ ID NO: 45 (NMS-67) and SEQ ID NO: 64 (NMS-115).

[26]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (B) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 3 (NMS-6), SEQ ID NO: 66 (NMS-118), SEQ ID NO: 67 (NMS-119), SEQ ID NO: 28 (NMS-33), SEQ ID NO: 72 (NMS-127), SEQ ID NO: 16 (NMS-20), SEQ ID NO: 82 (NMS-187) and SEQ ID NO: 25 (NMS-30).

[27]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (C) consists of a nucleotide sequence shown in SEQ ID NO: 12 (NMS-16).

[28]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (D) consists of a nucleotide sequence shown in SEQ ID NO: 4 (NMS-7).

[29]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (E) consists of a nucleotide sequence shown in SEQ ID NO: 90 (NMS-51).

[30]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (F) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 91 (NMS-52), SEQ ID NO: 28 (NMS-33) and SEQ ID NO: 25 (NMS-30), SEQ ID NO: 41 (NMS-61), SEQ ID NO: 24 (NMS-29), SEQ ID NO: 42 (NMS-62), SEQ ID NO: 43 (NMS-63), SEQ ID NO: 11 (NMS-15), SEQ ID NO: 67 (NMS-119), SEQ ID NO: 80 (NMS-161) and SEQ ID NO: 82 (NMS-187).

[31]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (G) consists of a nucleotide sequence shown in SEQ ID NO: 7 (NMS-10).

[32]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [23] above, wherein the antisense oligomer (H) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 4 (NMS-7), SEQ ID NO: 9 (NMS-12), SEQ ID NO: 10 (NMS-14) and SEQ ID NO: 14 (NMS-18).

[33]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [23] to [32] above, wherein the antisense oligomer is an oligonucleotide.

[34]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [33] above, wherein at least one sugar moiety and/or at least one phosphate bond moiety in nucleotides constituting the oligonucleotide is modified.

[35]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [34] above, wherein the at least one sugar moiety in nucleotides constituting the oligonucleotide is a ribose in which the -OH group at the 2′-position is substituted with any group selected from the group consisting of OR, R, R′OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R represents alkyl or aryl, and R′ represents alkylene).

[36]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [34] or [35] above, wherein the at least one phosphate bond moiety in nucleotides constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoroamidate bond and a boranophosphate bond.

[37]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [23] to [32] above, wherein the antisense oligomer is a morpholino oligomer.

[38]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [37] above, wherein the morpholino oligomer is a phosphorodiamidate morpholino oligomer.

[39]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to [37] or [38] above, whose 5′-terminal end is any one of the groups represented by chemical formulae (1) to (3) shown below.

[40]

A pharmaceutical composition comprising the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [23] to [39] above.

[41]

The pharmaceutical composition according to [40] above, which further comprises a pharmaceutically acceptable carrier.

[42]

The pharmaceutical composition according to [40] or [41] above for use in the treatment of an amyotrophic disease or a muscle wasting disease.

[43]

The pharmaceutical composition according to [42] above for use in the treatment of muscular dystrophy.

[44]

A method for prevention or treatment of an amyotrophic disease or a muscle wasting disease, which comprises administering a subject in need of prevention or treatment of an amyotrophic disease or a muscle wasting disease with a therapeutically effective amount of the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [23] to [39] above.

[45]

The method according to [44] above, wherein the amyotrophic disease or muscle wasting disease is muscular dystrophy.

[46]

The method according to [44] or [45] above, wherein the subject is a human subject.

[47]

Use of the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [23] to [39] above in the manufacture of a pharmaceutical composition for treatment of an amyotrophic disease or a muscle wasting disease.

[48]

The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to any one of [23] to [39] above for use in the treatment of an amyotrophic disease or a muscle wasting disease.

Effects of the Invention

Antisense oligomers according to some embodiments of the present invention allow induction of exon skipping in the myostatin gene. In addition, an amyotrophic disease or a muscle wasting disease can be prevented or treated when an antisense oligomer according to a preferred embodiment of the present invention or a pharmaceutically acceptable salt or hydrate thereof is administered to a subject in need of prevention or treatment of an amyotrophic disease or a muscle wasting disease.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 2 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 3 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 4 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 5 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 6 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 7 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 8 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 9 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 10 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 11 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 12 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 13 is a graph showing the efficiency of exon 2 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 14 is a graph showing the efficiency of exon 3 skipping in the human myostatin gene in a human rhabdomyosarcoma cell line (RD cells).

FIG. 15 shows the results of Test Example 2.

DESCRIPTION OF EMBODIMENTS

The present invention will be described in more detail below. The following embodiments are illustrated to describe the present invention, and it is not intended to limit the present invention only to these embodiments. The present invention can be implemented in various modes without departing from the spirit of the present invention.
It should be noted that all publications cited herein, including prior art documents, patent gazettes and other patent documents, are incorporated herein by reference. Moreover, this specification incorporates the contents disclosed in the specification and drawings of Japanese Patent Application No. 2015-18214 (filed on September 16, 2015), based on which the present application claims priority.
1. Antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof
The present invention provides an antisense oligomer which allows exon 2 skipping in the myostatin gene, or a pharmaceutically acceptable salt or hydrate thereof (hereinafter collectively referred to as “the antisense oligomer of the present invention”).
The following “antisense oligomer A of the present invention” and “antisense oligomer B of the present invention” may also be collectively referred to as “the antisense oligomer of the present invention.”
1.1. Antisense oligomer A of the Present Invention
The antisense oligomer A of the present invention is an antisense oligomer of 14 to 30 bases in length comprising connected two unit oligomers selected from the group consisting of (a) and (b) shown below, or a pharmaceutically acceptable salt or hydrate thereof:

wherein the first nucleotide sequence and the second nucleotide sequence are not contiguous to each other or do not overlap with each other.
The antisense oligomer A of the present invention is more specifically an antisense oligomer shown in (c) or (d) below, or a pharmaceutically acceptable salt or hydrate thereof:

(c-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene;
(c-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene;
(c-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene;
(c-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 166 to 210 from the 5′-terminal end of exon 2 in the human myostatin gene;
(c-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene; and (c-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene; or

(d-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions -1 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 196 to 233 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(d-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene; and

(d-7) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene.

Further, the antisense oligomer A of the present invention is more specifically an antisense oligomer shown in (e) or (f) below, or a pharmaceutically acceptable salt or hydrate thereof:

(f-1) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 1 to 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-2) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-3) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-4) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-5) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 211 to 225 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(f-6) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 271 to 282 from the 5′-terminal end of exon 2 in the mouse myostatin gene; and
(f-7) a unit oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence consisting of contiguous 7 to 15 bases selected from a nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene.
In the antisense oligomer A of the present invention, the term “gene” is intended to include not only a genomic gene, but also cDNA, precursor mRNA, and mRNA. The gene is preferably precursor mRNA, i.e., pre-mRNA.
Pre-mRNA transcribed from the myostatin gene contains three exons and two introns in the order of (5′-terminal end) exon 1, intron 1, exon 2, intron 2 and exon 3 (3′-terminal end). Pre-mRNA is spliced to generate mature mRNA. The nucleotide sequences of the human and mouse wild-type myostatin genes are known (RefSeq Accession No. NM_005259 (human) and RefSeq Accession No. NM 010834 (mouse), respectively). The nucleotide sequence of exon 2 in the wild-type myostatin gene is as shown below:
exon 2 (human): SEQ ID NO: 323; and
exon 2 (mouse): SEQ ID NO: 324.
In the above unit oligomer (c-1), the “nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 337.
In the above unit oligomer (c-2), the “nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 338.
In the above unit oligomer (c-3), the “nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 339.
In the above unit oligomer (c-4), the “nucleotide sequence located at positions 166 to 210 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 340.
In the above unit oligomer (c-5), the “nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 341.
In the above unit oligomer (c-6), the “nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 342.
In the above unit oligomer (d-1), the “nucleotide sequence located at positions −10 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 343.
In the above unit oligomer (d-2), the “nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 344.
In the above unit oligomer (d-3), the “nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 345.
In the above unit oligomer (d-4), the “nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 346.
In the above unit oligomer (d-5), the “nucleotide sequence located at positions 196 to 233 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 347.
In the above unit oligomer (d-6), the “nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 364.
In the above unit oligomer (d-7), the “nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 348.
In the above unit oligomer (e-1), the “nucleotide sequence located at positions -4 to 25 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 349.
In the above unit oligomer (e-2), the “nucleotide sequence located at positions 112 to 131 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 350.
In the above unit oligomer (e-3), the “nucleotide sequence located at positions 128 to 142 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 351.
In the above unit oligomer (e-4), the “nucleotide sequence located at positions 169 to 206 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 352.
In the above unit oligomer (e-5), the “nucleotide sequence located at positions 209 to 228 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 353.
In the above unit oligomer (e-6), the “nucleotide sequence located at positions 331 to 365 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 354.
In the above unit oligomer (f-1), the “nucleotide sequence located at positions 1 to 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 355.
In the above unit oligomer (f-2), the “nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 356.
In the above unit oligomer (f-3), the “nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 357.
In the above unit oligomer (f-4), the “nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 358.
In the above unit oligomer (f-5), the “nucleotide sequence located at positions 211 to 225 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 359.
In the above unit oligomer (f-6), the “nucleotide sequence located at positions 271 to 282 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 365.
In the above unit oligomer (f-7), the “nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 366.
The antisense oligomer A of the present invention has now been prepared to cause exon 2 skipping in the myostatin gene with the aim of modifying a protein encoded by the myostatin gene into a mutant protein lacking the function of myostatin. The “function of myostatin” refers to, for example, the function or activity to negatively control skeletal muscle mass. Thus, exon 2 in the myostatin gene to be skipped by the antisense oligomer A of the present invention includes not only wild-type, but also mutated forms.
More specifically, mutated exon 2 in the myostatin gene or a portion thereof is a polynucleotide shown in (a) or (b) below:
(a) a polynucleotide hybridizable under stringent conditions with a polynucleotide consisting of a nucleotide sequence complementary to any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 337 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 338 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 339 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 340 (a nucleotide sequence located at positions 166 to 210 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 341 (a nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 342 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 349 (a nucleotide sequence located at positions -4 to 25 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 350 (a nucleotide sequence located at positions 112 to 131 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 351 (a nucleotide sequence located at positions 128 to 142 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 352 (a nucleotide sequence located at positions 169 to 206 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 353 (a nucleotide sequence located at positions 209 to 228 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 354 (a nucleotide sequence located at positions 331 to 365 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 343 (a nucleotide sequence located at positions −10 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 344 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 345 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 346 (a nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 347 (a nucleotide sequence located at positions 196 to 233 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 364 (a nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 348 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 355 (a nucleotide sequence located at positions 1 to 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 356 (a nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 357 (a nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 358 (a nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 359 (a nucleotide sequence located at positions 211 to 255 from the 5% terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 365 (a nucleotide sequence located at positions 271 to 282 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 366 (a nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene); or
(b) a polynucleotide consisting of a nucleotide sequence sharing an identity of 90% or more with any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 337 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 338 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 339 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 340 (a nucleotide sequence located at positions 166 to 210 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 341 (a nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 342 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 349 (a nucleotide sequence located at positions -4 to 25 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 350 (a nucleotide sequence located at positions 112 to 131 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 351 (a nucleotide sequence located at positions 128 to 142 from the 5% terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 352 (a nucleotide sequence located at positions 169 to 206 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 353 (a nucleotide sequence located at positions 209 to 228 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 354 (a nucleotide sequence located at positions 331 to 365 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 343 (a nucleotide sequence located at positions −10 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 344 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 345 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 346 (a nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 347 (a nucleotide sequence located at positions 196 to 233 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 364 (a nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 348 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 355 (a nucleotide sequence located at positions Ito 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 356 (a nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 357 (a nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 358 (a nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 359 (a nucleotide sequence located at positions 211 to 255 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 365 (a nucleotide sequence located at positions 271 to 282 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 366 (a nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene).
As used herein, the term “polynucleotide” is intended to mean DNA or RNA.
As used herein, the expression “nucleotide sequence complementary” is not limited only to a nucleotide sequence forming Watson-Crick pairs with a target nucleotide sequence and also includes nucleotide sequences forming wobble base pairs with a target nucleotide sequence. In this regard, a Watson-Crick pair is intended to mean a base pair which forms hydrogen bonding between adenine and thymine, between adenine and uracil or between guanine and cytosine, whereas a wobble base pair is intended to mean a base pair which forms hydrogen bonding between guanine and uracil, between inosine and uracil, between inosine and adenine or between inosine and cytosine. Moreover, such a “nucleotide sequence complementary” does not necessarily have 100% complementarity to a target nucleotide sequence and may contain non-complementary bases (e.g., 1 to 3 bases, 1 or 2 bases, or a single base) to the target nucleotide sequence.
As used herein, the expression “polynucleotide hybridizable under stringent conditions” is intended to mean, for example, an antisense oligomer that can be obtained by means of colony hybridization, plaque hybridization, Southern hybridization or other hybridization techniques using, as a probe, the whole or a part of a polynucleotide consisting of a nucleotide sequence complementary to any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 337 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 338 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 339 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 340 (a nucleotide sequence located at positions 166 to 210 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 341 (a nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 342 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 349 (a nucleotide sequence located at positions −4 to 25 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 350 (a nucleotide sequence located at positions 112 to 131 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 351 (a nucleotide sequence located at positions 128 to 142 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 352 (a nucleotide sequence located at positions 169 to 206 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 353 (a nucleotide sequence located at positions 209 to 228 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 354 (a nucleotide sequence located at positions 331 to 365 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 343 (a nucleotide sequence located at positions −10 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 344 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 345 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 346 (a nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 347 (a nucleotide sequence located at positions 196 to 233 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 364 (a nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 348 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 355 (a nucleotide sequence located at positions 1 to 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 356 (a nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 357 (a nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 358 (a nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 359 (a nucleotide sequence located at positions 211 to 255 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 365 (a nucleotide sequence located at positions 271 to 282 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 366 (a nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene). For hybridization, it is possible to use techniques as described in, e.g., “Sambrook & Russell, Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor, Laboratory Press 2012” and “Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons 1987-1997.”
As used herein, the term “stringent conditions” may be any of low stringent conditions, moderately stringent conditions and high stringent conditions. “Low stringent conditions” refer to, for example, conditions of 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide and 32° C. Likewise, “moderately stringent conditions” refer to, for example, conditions of 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide and 42° C. or conditions of 5×SSC, 1% SDS, 50 mM Tris-HCl (pH 7.5), 50% formamide and 42° C. “High stringent conditions” refer to, for example, conditions of (1) 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide and 50° C., (2) 0.2×SSC, 0.1% SDS and 60° C., (3) 0.2×SSC, 0.1% SDS and 62° C., (4) 0.2×SSC, 0.1% SDS and 65° C., or (5) 0.1×SSC, 0.1% SDS and 65° C., but are not limited thereto. Under these conditions, it can be expected that an antisense oligomer having a higher sequence identity is more efficiently obtained at a higher temperature. However, the stringency of hybridization would be affected by a plurality of factors, including temperature, probe concentration, probe length, ionic strength, reaction time, salt concentration and so on. Those skilled in the art would be able to achieve the same stringency by selecting these factors as appropriate.
It should be noted that if a commercially available kit is used for hybridization, an Alkphos Direct Labelling and Detection System (GE Healthcare) may be used for this purpose, by way of example. In this case, hybridization may be accomplished in accordance with the protocol attached to the kit, i.e., a membrane may be incubated overnight with a labeled probe and then washed with a primary washing buffer containing 0.1% (w/v) SDS under conditions of 55° C. to detect the hybridized antisense oligomer. Alternatively, if a commercially available reagent (e.g., PCR labeling mix (Roche Diagnostics)) is used for digoxigenin (DIG) labeling of a probe during probe preparation based on the whole or a part of a nucleotide sequence complementary to any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 337 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 338 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 339 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 340 (a nucleotide sequence located at positions 166 to 210 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 341 (a nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 342 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 349 (a nucleotide sequence located at positions -4 to 25 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 350 (a nucleotide sequence located at positions 112 to 131 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 351 (a nucleotide sequence located at positions 128 to 142 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 352 (a nucleotide sequence located at positions 169 to 206 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 353 (a nucleotide sequence located at positions 209 to 228 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 354 (a nucleotide sequence located at positions 331 to 365 from the 5′-terminal end of exon .2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 343 (a nucleotide sequence located at positions −10 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 344 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 345 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 346 (a nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 347 (a nucleotide sequence located at positions 196 to 233 from the 5% terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 364 (a nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 348 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 355 (a nucleotide sequence located at positions 1 to 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 356 (a nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 357 (a nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 358 (a nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 359 (a nucleotide sequence located at positions 211 to 255 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 365 (a nucleotide sequence located at positions 271 to 282 from the 5′ -terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 366 (a nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene), a DIG nucleic acid detection kit (Roche Diagnostics) may be used for detection of hybridization.
In addition to those listed above, other hybridizable antisense oligomers include polynucleotides sharing an identity of 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more with any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 337 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 338 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 339 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 340 (a nucleotide sequence located at positions 166 to 210 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 341 (a nucleotide sequence located at positions 204 to 233 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 342 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 349 (a nucleotide sequence located at positions -4 to 25 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 350 (a nucleotide sequence located at positions 112 to 131 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 351 (a nucleotide sequence located at positions 128 to 142 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 352 (a nucleotide sequence located at positions 169 to 206 from the 5 ‘-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 353 (a nucleotide sequence located at positions 209 to 228 from the 5’-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 354 (a nucleotide sequence located at positions 331 to 365 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 343 (a nucleotide sequence located at positions −10 to 65 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 344 (a nucleotide sequence located at positions 91 to 135 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 345 (a nucleotide sequence located at positions 121 to 155 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 346 (a nucleotide sequence located at positions 151 to 210 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 347 (a nucleotide sequence located at positions 196 to 233 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 364 (a nucleotide sequence located at positions 266 to 295 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 348 (a nucleotide sequence located at positions 326 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 355 (a nucleotide sequence located at positions 1 to 18 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 356 (a nucleotide sequence located at positions 116 to 131 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 357 (a nucleotide sequence located at positions 130 to 140 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 358 (a nucleotide sequence located at positions 160 to 206 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 359 (a nucleotide sequence located at positions 211 to 255 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 365 (a nucleotide sequence located at positions 271 to 282 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 366 (a nucleotide sequence located at positions 341 to 365 from the 5′-terminal end of exon 2 in the mouse myostatin gene), as calculated by the homology search software BLAST using default parameters.
It should be noted that the identity of nucleotide sequences can be determined by BLAST (Basic Local Alignment Search Tool) (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc. Natl. Acad. Sci. USA 90: 5873, 1993). If BLAST is used, default parameters in each program may be used.
The unit oligomers (hereinafter also simply referred to as “units”) shown in (c) to (f) above each have a size of 7 to 15 bases in length, preferably 8 to 15 bases in length, 9 to 15 bases in length, 10 to 15 bases in length, 10 to 14 bases in length, 10 to 13 bases in length or 11 to 13 bases in length. The respective units shown in (c) to (1) above may be of the same or different size.
In the above antisense oligomer (c), either of two units selected from the group consisting of the above units (c-1) to (c-6) may be located at the 5′-terminal side.
In the above antisense oligomer (d), either of two units selected from the group consisting of the above units (d-1) to (d-7) may be located at the 5′-terminal side.
In the above antisense oligomer (e), either of two units selected from the group consisting of the above units (e-1) to (e-6) may be located at the 5′-terminal side.
In the above antisense oligomer (e), either of two units selected from the group consisting of the above units (f-1) to (f-7) may be located at the 5′-terminal side.
As used here, the term “connected” is intended to mean that two units are directly connected to each other. Namely, when two units are connected, it means that the 3′-terminal end of the unit located at the 5′-terminal side and the 5′-terminal end of the unit located at the 3′-terminal side form a phosphate bond or any of the following groups:
(wherein X represents —OH, —CH₂R¹, —O—CH₂R¹, —S—CH₂R¹, —NR²R³or F;
R¹represents H or alkyl;
R²and R³, which may be the same or different, each represent H, alkyl, cycloalkyl or aryl;
Y₁represents O, S, CH₂or NR¹;
Y₂represents O, S or NR¹; and
Z represents O or S).
In a preferred embodiment of the antisense oligomer A of the present invention, the above antisense oligomer (c) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 103 (NMS-48), SEQ ID NO: 116 (NMS-89), SEQ ID NO: 117 (NMS-90), SEQ ID NO: 120 (NMS-93), SEQ ID NO: 128 (NMS-101), SEQ ID NO: 131 (NMS-104), SEQ ID NO: 136 (NMS-113), SEQ ID NO: 137 (NMS-117), SEQ ID NO: 140 (NMS-123), SEQ ID NO: 145 (NMS-136), SEQ ID NO: 146 (NMS-139), SEQ ID NO: 147 (NMS-140), SEQ ID NO: 148 (NMS-141), SEQ ID NO: 149 (NMS-142), SEQ ID NO: 152 (NMS-145), SEQ ID NO: 155 (NMS-148), SEQ ID NO: 156 (NMS-149), SEQ ID NO: 157 (NMS-150), SEQ ID NO: 159 (NMS-152), SEQ ID NO: 162 (NMS-156), SEQ ID NO: 163 (NMS-157), SEQ ID NO: 165 (NMS-162), SEQ ID NO: 166 (NMS-163), SEQ ID NO: 167 (NMS-164), SEQ ID NO: 168 (NMS-166), SEQ ID NO: 169 (NMS-167), SEQ ID NO: 170 (NMS-168), SEQ ID NO: 171 (NMS-169), SEQ ID NO: 176 (NMS-174), SEQ ID NO: 177 (NMS-175), SEQ ID NO: 178 (NMS-176), SEQ ID NO: 179 (NMS-177), SEQ ID NO: 180 (NMS-178), SEQ ID NO: 183 (NMS-181), SEQ ID NO: 187 (NMS-185), SEQ ID NO: 189 (NMS-188), SEQ ID NO: 190 (NMS-189), SEQ ID NO: 191 (NMS-190), SEQ ID NO: 192 (NMS-191), SEQ ID NO: 193 (NMS-192), SEQ ID NO: 196 (NMS-195), SEQ ID NO: 199 (NMS-198), SEQ ID NO: 200 (NMS-199), SEQ ID NO: 201 (NMS-200), SEQ ID NO: 203 (NMS-202), SEQ ID NO: 204 (NMS-203), SEQ ID NO: 206 (NMS-206), SEQ ID NO: 208 (NMS-208), SEQ ID NO: 212 (NMS-212), SEQ ID NO: 213 (NMS-213), SEQ ID NO: 214 (NMS-214), SEQ ID NO: 215 (NMS-215), SEQ ID NO: 217 (NMS-217), SEQ ID NO: 225 (NMS-225), SEQ ID NO: 226 (NMS-228), SEQ ID NO: 228 (NMS-230), SEQ ID NO: 229 (NMS-231), SEQ ID NO: 231 (NMS-233), SEQ ID NO: 232 (NMS-234), SEQ ID NO: 233 (NMS-235), SEQ ID NO: 236 (NMS-240), SEQ ID NO: 237 (NMS-241), SEQ ID NO: 240 (NMS-244), SEQ ID NO: 243 (NMS-247), SEQ ID NO: 244 (NMS-248), SEQ ID NO: 245 (NMS-249), SEQ ID NO: 246 (NMS-250), SEQ ID NO: 247 (NMS-251), SEQ ID NO: 248 (NMS-252), SEQ ID NO: 252 (NMS-256), SEQ ID NO: 261 (NMS-272), SEQ ID NO: 273 (NMS-284), SEQ ID NO: 274 (NMS-285), SEQ ID NO: 275 (NMS-286) and SEQ ID NO: 277 (NMS-297).
In another preferred embodiment of the antisense oligomer A of the present invention, the above antisense oligomer (d) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 95 (NMS-38), SEQ ID NO: 96 (NMS-39), SEQ ID NO: 107 (NMS-66), SEQ ID NO: 223 (NMS-223), SEQ ID NO: 234 (NMS-238), SEQ ID NO: 235 (NMS-239), SEQ ID NO: 242 (NMS-246), SEQ ID NO: 249 (NMS-253), SEQ ID NO: 250 (NMS-254), SEQ ID NO: 251 (NMS-255), SEQ ID NO: 257 (NMS-268), SEQ ID NO: (NMS-280), SEQ ID NO: (NMS-281), SEQ ID NO: (NMS-282), SEQ ID NO: (NMS-288), SEQ ID NO: (NMS-289), SEQ ID NO: (NMS-290), SEQ ID NO: (NMS-292), SEQ ID NO: (NMS-293), SEQ ID NO: (NMS-294), SEQ ID NO: (NMS-295), SEQ ID NO: (NMS-298), SEQ ID NO: (NMS-299), SEQ ID NO: (NMS-300), SEQ ID NO: (NMS-302) and SEQ ID NO: (NMS-303).
In a particularly preferred embodiment of the antisense oligomer A of the present invention, the above antisense oligomer (c) or (e) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 171 (NMS-169), SEQ ID NO: 192 (NMS-191), SEQ ID NO: 245 (NMS-249) and SEQ ID NO: 231 (NMS-233).
The expression “allowing exon 2 skipping in the myostatin gene” is intended to mean that upon binding the antisense oligomer A of the present invention to a transcript (e.g., pre-mRNA) of the human myostatin gene, the transcript is spliced to delete the whole or a part of exon 2 to thereby form mature mRNA which encodes mutant myostatin lacking the function of myostatin.
The antisense oligomer A of the present invention does not necessarily have a nucleotide sequence which is 100% complementary to a target sequence, as long as it allows exon 2 skipping in the myostatin gene. For example, the oligomer B of the present invention may contain non-complementary bases (e.g., 1 to 3 bases, 1 or 2 bases, or a single base) to the target sequence.
The term “binding” is used here to mean that once the antisense oligomer A of the present invention has been mixed with a transcript of the myostatin gene, both will be hybridized with each other under physiological conditions to form a duplex. The expression “under physiological conditions” is used here to mean conditions adjusted to mimic in vivo pH, salt composition and temperature, as exemplified by conditions of 25° C. to 40° C., preferably 37° C., pH 5 to 8, preferably pH 7.4, and a sodium chloride concentration of 150 mM.
The efficiency of skipping is as described later.
The antisense oligomer A of the present invention may be an oligonucleotide, a morpholino oligomer or a peptide nucleic acid oligomer. Such an oligonucleotide, a morpholino oligomer or a peptide nucleic acid oligomer is as described later.
1.2. Antisense Oligomer B of the Present Invention
The antisense oligomer B of the present invention is any one antisense oligomer selected from the group consisting of (A) to (H) shown below, or a pharmaceutically acceptable salt or hydrate thereof:

(A) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene;
(B) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene;
(C) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene;
(D) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene;
(E) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(F) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene;
(G) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene; and
(H) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene.

In a more preferred embodiment, the antisense oligomer B of the present invention is any one antisense oligomer selected from the group consisting of (I) to (L) shown below, or a pharmaceutically acceptable salt or hydrate thereof:

(I) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene;
(J) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene, wherein the 3 ‘-terminal base of the nucleotide sequence of 14 to 30 bases in length is a base located at position 140 from the 5’-terminal end of said exon 2;
(K) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene; and
(L) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene.

In the antisense oligomer B of the present invention, the term “gene” is intended to include not only a genomic gene, but also cDNA, precursor mRNA, and mRNA. The gene is preferably precursor mRNA, i.e., pre-mRNA.
Pre-mRNA transcribed from the myostatin gene contains three exons and two introns in the order of (5′-terminal end) exon 1, intron 1, exon 2, intron 2 and exon 3 (3′-terminal end). Pre-mRNA is spliced to generate mature mRNA. The nucleotide sequences of the human and mouse wild-type myostatin genes are known (RefSeq Accession No. NM_005259 (human) and RefSeq Accession No. NM_010834 (mouse)). The nucleotide sequence of exon 2 in the wild-type myostatin gene is as shown below:
exon 2 (human): SEQ ID NO: 323; and
exon 2 (mouse): SEQ ID NO: 324.
A nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 (human) is shown in SEQ ID NO: 325.
A nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 (mouse) is shown in SEQ ID NO: 326.
In the above antisense oligomer (A), the “nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 327.
In the above antisense oligomer (B), the “nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 328.
In the above antisense oligomer (C), the “nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 329.
In the above antisense oligomer (D), the “nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 330.
In the above antisense oligomer (E), the “nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 331.
In the above antisense oligomer (F), the “nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 332.
In the above antisense oligomer (G), the “nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 333.
In the above antisense oligomer (H), the “nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene” is shown in SEQ ID NO: 334.
In the above antisense oligomer (I), the “nucleotide sequence located at positions -10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 335.
In the above antisense oligomer (J), the “nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 336.
In the above antisense oligomer (K), the “nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 362.
In the above antisense oligomer (L), the “nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene” is shown in SEQ ID NO: 363.
The antisense oligomer B of the present invention has now been prepared to cause exon 2 skipping in the myostatin gene with the aim of modifying a protein encoded by the myostatin gene into a mutant protein lacking the function of myostatin. The “function of myostatin” refers to, for example, the function or activity to negatively control skeletal muscle mass. Thus, exon 2 in the myostatin gene to be skipped by the antisense oligomer B of the present invention includes not only wild-type, but also mutated forms.
More specifically, mutated exon 2 in the myostatin gene or a portion thereof is a polynucleotide shown in (a) or (b) below:
(a) a polynucleotide hybridizable under stringent conditions with a polynucleotide consisting of a nucleotide sequence complementary to any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 325 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 327 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 328 (a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 329 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 330 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 335 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 336 (a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 362 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 363 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 326 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 331 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 332 (a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 333 (a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 334 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene); or
(b) a polynucleotide consisting of a nucleotide sequence sharing an identity of 90% or more with any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 325 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 327 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 328 (a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 329 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 330 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 335 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 336 (a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 362 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 363 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 326 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 331 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 332 (a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 333 (a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 334 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene).
As used herein, the term “polynucleotide” is intended to mean DNA or RNA.
As used herein, the expression “nucleotide sequence complementary” is not limited only to a nucleotide sequence forming Watson-Crick pairs with a target nucleotide sequence and also includes nucleotide sequences forming wobble base pairs with a target nucleotide sequence. In this regard, a Watson-Crick pair is intended to mean a base pair which forms hydrogen bonding between adenine and thymine, between adenine and uracil or between guanine and cytosine, whereas a wobble base pair is intended to mean a base pair which forms hydrogen bonding between guanine and uracil, between inosine and uracil, between inosine and adenine or between inosine and cytosine. Moreover, such a “nucleotide sequence complementary” does not necessarily have 100% complementarity to a target nucleotide sequence and may contain non-complementary bases (e.g., 1 to 3 bases, 1 or 2 bases, or a single base) to the target nucleotide sequence.
As used herein, the expression “polynucleotide hybridizable under stringent conditions” is intended to mean, for example, an antisense oligomer that can be obtained by means of colony hybridization, plaque hybridization, Southern hybridization or other hybridization techniques using, as a probe, the whole or a part of a polynucleotide consisting of a nucleotide sequence complementary to any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 325 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 327 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 328 (a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 329 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 330 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 335 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 336 (a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 362 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 363 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 326 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 331 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 332 (a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 333 (a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 334 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene). For hybridization, it is possible to use techniques as described in, e.g., “Sambrook & Russell, Molecular Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor, Laboratory Press 2012” and “Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons 1987-1997.”
As used herein, the term “stringent conditions” may be any of low stringent conditions, moderately stringent conditions and high stringent conditions. “Low stringent conditions” refer to, for example, conditions of 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide and 32° C. Likewise, “moderately stringent conditions” refer to, for example, conditions of 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide and 42° C. or conditions of 5×SSC, 1% SDS, 50 mM Tris-HCl (pH 7.5), 50% formamide and 42° C. “High stringent conditions” refer to, for example, conditions of (1) 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide and 50° C., (2) 0.2×SSC, 0.1% SDS and 60° C., (3) 0.2×SSC, 0.1% SDS and 62° C., (4) 0.2×SSC, 0.1% SDS and 65° C., or (5) 0.1×SSC, 0.1% SDS and 65° C., but are not limited thereto. Under these conditions, it can be expected that an antisense oligomer having a higher sequence identity is more efficiently obtained at a higher temperature. However, the stringency of hybridization would be affected by a plurality of factors, including temperature, probe concentration, probe length, ionic strength, reaction time, salt concentration and so on. Those skilled in the art would be able to achieve the same stringency by selecting these factors as appropriate.
It should be noted that if a commercially available kit is used for hybridization, an Alkphos Direct Labelling and Detection System (GE Healthcare) may be used for this purpose, by way of example. In this case, hybridization may be accomplished in accordance with the protocol attached to the kit, i.e., a membrane may be incubated overnight with a labeled probe and then washed with a primary washing buffer containing 0.1% (w/v) SDS under conditions of 55° C. to detect the hybridized antisense oligomer. Alternatively, if a commercially available reagent (e.g., PCR labeling mix (Roche Diagnostics)) is used for digoxigenin (DIG) labeling of a probe during probe preparation based on the whole or a part of a nucleotide sequence complementary to any nucleotide sequence selected from the group consisting of SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 325 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 327 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 328 (a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 329 (a nucleotide sequence located at positions 146 to 180 from the 5′ -terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 330 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 335 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 336 (a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 362 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 363 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 326 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 331 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 332 (a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 333 (a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 334 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene), a DIG nucleic acid detection kit (Roche Diagnostics) may be used for detection of hybridization.
In addition to those listed above, other hybridizable antisense oligomers include polynucleotides sharing an identity of 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more with SEQ ID NO: 323 (exon 2 in the human myostatin gene), SEQ ID NO: 325 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 327 (a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 328 (a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 329 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 330 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 335 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 336 (a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 362 (a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 363 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene), SEQ ID NO: 324 (exon 2 in the mouse myostatin gene), SEQ ID NO: 326 (a nucleotide sequence located at position −10 from the 5′-terminal end up to the 3′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 331 (a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 332 (a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene), SEQ ID NO: 333 (a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene) and SEQ ID NO: 334 (a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene), as calculated by the homology search software BLAST using default parameters.
It should be noted that the identity of nucleotide sequences can be determined by BLAST (Basic Local Alignment Search Tool) (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc. Natl. Acad. Sci. USA 90: 5873, 1993). If BLAST is used, default parameters in each program may be used.
The expression “allowing exon 2 skipping in the myostatin gene” is intended to mean that upon binding the antisense oligomer B of the present invention to a transcript (e.g., pre-mRNA) of the human myostatin gene, the transcript is spliced to delete the whole or a part of exon 2 to thereby form mature mRNA which encodes mutant myostatin lacking the function of myostatin.
The antisense oligomer B of the present invention does not necessarily have a nucleotide sequence which is 100% complementary to a target sequence, as long as it allows exon 2 skipping in the myostatin gene. For example, the antisense oligomer B of the present invention may contain non-complementary bases (e.g., 1 to 3 bases, 1 or 2 bases, or a single base) to the target sequence.
The term “binding” is used here to mean that once the antisense oligomer B of the present invention has been mixed with a transcript of the myostatin gene, both will be hybridized with each other under physiological conditions to form a duplex. The expression “under physiological conditions” is used here to mean conditions adjusted to mimic in vivo pH, salt composition and temperature, as exemplified by conditions of 25° C. to 40° C., preferably 37° C., pH 5 to 8, preferably pH 7.4, and a sodium chloride concentration of 150 mM.
In another preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (A) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 13 (NMS-17), SEQ ID NO: 76 (NMS-138), SEQ ID NO: 68 (NMS-120), SEQ ID NO: 75 (NMS-137), SEQ ID NO: 51 (NMS-76), SEQ ID NO: 52 (NMS-79), SEQ ID NO: 54 (NMS-81), SEQ ID NO: 55 (NMS-82), SEQ ID NO: 56 (NMS-83), SEQ ID NO: 53 (NMS-80), SEQ ID NO: 33 (NMS-49), SEQ ID NO: 63 (NMS-114), SEQ ID NO: 69 (NMS-124), SEQ ID NO: 70 (NMS-125), SEQ ID NO: 61 (NMS-110), SEQ ID NO: 31 (NMS-46), SEQ ID NO: 34 (NMS-50), SEQ ID NO: 50 (NMS-75), SEQ ID NO: 45 (NMS-67) and SEQ ID NO: 64 (NMS-115).
In a preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (B) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 3 (NMS-6), SEQ ID NO: 66 (NMS-118), SEQ ID NO: 67 (NMS-119), SEQ ID NO: 28 (NMS-33), SEQ ID NO: 72 (NMS-127), SEQ ID NO: 16 (NMS-20), SEQ ID NO: 82 (NMS-187) and SEQ ID NO: 25 (NMS-30).
In another preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (C) consists of a nucleotide sequence shown in SEQ ID NO: 12 (NMS-16).
In another preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (D) consists of a nucleotide sequence shown in SEQ ID NO: 4 (NMS-7).
In yet another preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (E) consists of a nucleotide sequence shown in SEQ ID NO: 90 (NMS-51).
In yet another preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (F) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 91 (NMS-52), SEQ ID NO: 28 (NMS-33) and SEQ ID NO: 25 (NMS-30), SEQ ID NO: 41 (NMS-61), SEQ ID NO: 24 (NMS-29), SEQ ID NO: 42 (NMS-62), SEQ ID NO: 43 (NMS-63), SEQ ID NO: 11 (NMS-15), SEQ ID NO: 67 (NMS-119), SEQ ID NO: 80 (NMS-161) and SEQ ID NO: 82 (NMS-187).
In yet another preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (G) consists of a nucleotide sequence shown in SEQ ID NO: 7 (NMS-10).
In yet another preferred embodiment of the antisense oligomer B of the present invention, the above antisense oligomer (H) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 4 (NMS-7), SEQ ID NO: 9 (NMS-12), SEQ ID NO: 10 (NMS-14) and SEQ ID NO: 14 (NMS-18).
The efficiency of skipping is as described later.
The antisense oligomer B of the present invention may be an oligonucleotide, a morpholino oligomer or a peptide nucleic acid oligomer. Such an oligonucleotide, a morpholino oligomer or a peptide nucleic acid oligomer is as described later.
1.3. Skipping Efficiency
To confiiui whether or not exon skipping was caused in the myostatin gene, the antisense oligomer of the present invention may be transfected into myostatin-expressing cells (e.g., human rhabdomyosarcoma cells) and a region around the exon in mRNA of the myostatin gene may be amplified by RT-PCR from the total RNA of the above myostatin-expressing cells, followed by nested PCR or sequencing analysis on the PCR amplification product.
The efficiency of skipping may be determined as follows: mRNA of the myostatin gene is collected from test cells and the mRNA is measured for the polynucleotide level “A” in the band with exon skipping and the polynucleotide level “B” in the band without exon skipping, followed by calculation based on these measured values of “A” and “B” according to the following equation.
Skipping efficiency (%)={A/(A+B)}×100
In a preferred embodiment, the antisense oligomer of the present invention causes exon skipping with an efficiency of 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more.
As to the calculation of skipping efficiency, reference may be made to WO2012/029986.
1.4. Oligonucleotide, Morpholino Oligomer or Peptide Nucleic Acid Oligomer
The antisense oligomer of the present invention may be exemplified by an oligonucleotide, a morpholino oligomer or a peptide nucleic acid (PNA) oligomer, each being 14 to 30 bases in length. The antisense oligomer of the present invention is preferably 15 to 29 bases, 16 to 28 bases, 17 to 27 bases or 18 to 26 bases in length, and is preferably a morpholino oligomer.
The above oligonucleotide (hereinafter referred to as “the oligonucleotide of the present invention”) is an antisense oligomer according to the present invention, whose constituent unit is a nucleotide, and such a nucleotide may be any of a ribonucleotide, a deoxyribonucleotide or a modified nucleotide.
A modified nucleotide refers to a ribonucleotide or deoxyribonucleotide whose nucleobase, sugar moiety and phosphate bond moiety are all or partly modified.
In the present invention, examples of a nucleobase include adenine, guanine, hypoxanthine, cytosine, thymine, uracil, or modified bases thereof. Such modified bases may be exemplified by pseudouracil, 3-methyluracil, dihydrouracil, 5-alkylcytosines (e.g., 5-methylcytosine), 5-alkyluracils (e.g., 5-ethyluracil), 5-halouracils (e.g., 5-bromouracil), 6-azapyrimidine, 6-alkylpyrimidines (e.g., 6-methyluracil), 2-thiouracil, 4-thiouracil, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, 1-methyladenine, 1-methylhypoxanthine, 2,2-dimethylguanine, 3-methylcytosine, 2-methyladenine, 2-methylguanine, N6-methyladenine, 7-methylguanine, 5-methoxyaminomethyl-2-thiouracil, 5-methylaminomethyluracil, 5-methylcarbonylmethyluracil, 5-methyloxyuracil, 5-methyl-2-thiouracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid, 2-thiocytosine, purine, 2,6-diaminopurine, 2-aminopurine, isoguanine, indole, imidazole, xanthine and so on, but are not limited thereto.
Modifications to the sugar moiety may be exemplified by modifications at the 2′-position of ribose and modifications at the other positions of sugar. Examples of modifications at the 2′-position of ribose include modifications intended to replace the —OH group at the 2′-position of ribose with OR, R, R′OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br or I, wherein R represents alkyl or aryl, and R′ represents alkylene.
Examples of modifications at the other positions of sugar include replacement of O with S at the 4′-position of ribose or deoxyribose, and bridging between 2′- and 4′-positions of sugar, as exemplified by LNAs (locked nucleic acids) or ENAs (2′-O,4′-C-ethylene-bridged nucleic acids), but are not limited thereto.
Modifications to the phosphate bond moiety may be exemplified by modifications intended to replace the phosphodiester bond with a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoroamidate bond or a boranophosphate bond (Enya et al: Bioorganic & Medicinal Chemistry, 2008, 18, 9154-9160) (see, e.g., JP WO2006/129594 and JP WO2006/038608).
In the present invention, alkyl is preferably a linear or branched alkyl containing 1 to 6 carbon atoms. More specifically, examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl and isohexyl. Such an alkyl may be substituted with 1 to 3 substituents including halogen, alkoxy, cyano, nitro, etc.
In the present invention, cycloalkyl is preferably a cycloalkyl containing 5 to 12 carbon atoms. More specifically, examples include cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl.
In the present invention, halogens include fluorine, chlorine, bromine and iodine. Alkoxy may be a linear or branched alkoxy containing 1 to 6 carbon atoms, as exemplified by methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy, isohexyloxy and so on. Particularly preferred is an alkoxy containing 1 to 3 carbon atoms.
In the present invention, aryl is preferably an aryl containing 6 to 10 carbon atoms. More specifically, examples include phenyl, α-naphthyl and β-naphthyl. Particularly preferred is phenyl. Such an aryl may be substituted with 1 to 3 substituents including alkyl, halogen, alkoxy, cyano, nitro, etc.
In the present invention, alkylene is preferably a linear or branched alkylene containing 1 to 6 carbon atoms. More specifically, examples include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, 2-(ethyl)trimethylene and 1-(methyl)tetramethylene.
In the present invention, acyl may be a linear or branched alkanoyl or an aroyl. Examples of such an alkanoyl include formyl, acetyl, 2-methylacetyl, 2,2-dimethylacetyl, propionyl, butyryl, isobutyryl, pentanoyl, 2,2-dimethylpropionyl, hexanoyl and so on. Examples of an aroyl include benzoyl, toluoyl and naphthoyl. Such an aroyl may be substituted at any substitutable position and may be substituted with alkyl(s).
The oligonucleotide of the present invention is preferably an antisense oligomer according to the present invention, whose constituent unit is a group represented by the following general formula, in which the —OH group at the 2′-position of ribose is substituted with methoxy and the phosphate bond moiety is a phosphorothioate bond:
(wherein Base represents a nucleobase).
The oligonucleotide of the present invention may be readily synthesized with various automatic synthesizers (e.g., FOCUS (Aapptec), AKTA oligopilot plus 10/100 (GE Healthcare)), or alternatively, its synthesis may be entrusted to a third party (e.g., Promega, Takara, or Japan Bio Services), etc.
The morpholino oligomer of the present invention is an antisense oligomer according to the present invention, whose constituent unit is a group represented by the following general formula:
(wherein Base is the same as defined above; and
W represents a group represented by any of the following formulae:
(wherein X represents —CH₂R¹, —O—CH₂R¹, —S—CH₂R¹, —NR²R³or F;
R¹represents H or alkyl;
R²and R³, which may be the same or different, each represent H, alkyl, cycloalkyl or aryl;
Y₁represents O, S, CH₂or NR¹;
Y₂represents O, S or NR¹; and
Z represents O or S)).
The morpholino oligomer is preferably an oligomer whose constituent unit is a group represented by the following formula (i.e., a phosphorodiamidate morpholino oligomer (hereinafter referred to as “PMO”)):
(wherein Base, R²and R³are the same as defined above).
For example, the morpholino oligomer may be prepared in accordance with WO1991/009033 or WO2009/064471. In particular, PMO may be prepared in accordance with the procedures described in WO2009/064471 or may be prepared in accordance with the procedures shown below.
[Process for PMO Preparation]
As one embodiment of PMO, a compound represented by the following general formula (I) (hereinafter referred to as PMO (I)) may be given by way of example:
[wherein each Base, R²and R³are the same as defined above; and
n is any integer in the range of 1 to 99, preferably any integer in the range of 13 to 29, 14 to 28 or 15 to 27, 16 to 26, 17 to 25].
PMO (I) may be prepared in accordance with known procedures, for example, by conducting the operations shown in the following steps.
Compounds and reagents used in the following steps are not limited in any way as long as they are commonly used for PMO preparation.
Moreover, all the following steps may be accomplished by the liquid phase method or the solid phase method (in accordance with instruction manuals or using a commercially available solid phase automatic synthesizer). When PMO is prepared by the solid phase method, it is desirable to use an automatic synthesizer in terms of simple operation and accurate synthesis.
(1) Step A:
This is a step where a compound represented by the following general formula (II) (hereinafter referred to as compound (II)) is treated with an acid to prepare a compound represented by the following general formula (III) (hereinafter referred to as compound (III)):
[wherein n, R²and R³are the same as defined above;
each B^Pindependently represents a nucleobase which may be protected;
T represents a trityl group, a monomethoxytrityl group or a dimethoxytrityl group; and
L represents hydrogen, acyl or a group represented by the following general formula (IV) (hereinafter referred to as group (IV))]:
“Nucleobases” possible for BP may be exemplified by the same “nucleobases” as listed for Base, provided that amino groups or hydroxyl groups in these nucleobases for BP may be protected.
Protecting groups for these amino groups are not limited in any way as long as they are used as protecting groups for nucleic acids. More specifically, examples include benzoyl, 4-methoxybenzoyl, acetyl, propionyl, butyryl, isobutyryl, phenylacetyl, phenoxyacetyl, 4-tert-butylphenoxyacetyl, 4-isopropylphenoxyacetyl, and (dimethylamino)methylene. Protecting groups for hydroxyl groups include, for example, 2-cyanoethyl, 4-nitrophenethyl, phenylsulfonylethyl, methylsulfonylethyl, trimethylsilylethyl, phenyl which may be substituted with 1 to 5 electron withdrawing groups at any substitutable position(s), diphenylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, methylphenylcarbamoyl, 1-pyrrolidinylcarbamoyl, morpholinocarbamoyl, 4-(tert-butylcarboxy)benzyl, 4-[(dimethylamino)carboxy]benzyl, and 4-(phenylcarboxy)benzyl (see, e.g., WO2009/064471).
The “solid carrier” is not limited in any way as long as it is a carrier available for use in the solid phase reaction of nucleic acids, but it is desirable to use, for example, a carrier which (i) is sparingly soluble in reagents available for use in the synthesis of morpholino nucleic acid derivatives (e.g., dichloromethane, acetonitrile, tetrazole, N-methylimidazole, pyridine, acetic anhydride, lutidine, trifluoroacetic acid), (ii) is chemically stable against the reagents available for use in the synthesis of morpholino nucleic acid derivatives, (iii) can be chemically modified, (iv) can be loaded with desired morpholino nucleic acid derivatives, (v) has strength sufficient to withstand high pressure during processing, and (vi) has a certain range of particle size and distribution. More specifically, examples include swelling polystyrenes (e.g., aminomethyl polystyrene resin crosslinked with 1% divinylbenzene (200 to 400 mesh) (2.4 to 3.0 mmol/g) (Tokyo Chemical Industry Co., Ltd., Japan), Aminomethylated Polystyrene Resin HCl [divinylbenzene 1%, 100 to 200 mesh] (Peptide Institute, Inc., Japan)), non-swelling polystyrenes (e.g., Primer Support (GE Healthcare)), PEG chain-liked polystyrenes (e.g., NH2-PEG resin (Watanabe Chemical Industries, Ltd., Japan), TentaGel resin), controlled pore glass (CPG) (e.g., a product of CPG Inc.), oxalylated controlled pore glass (see, e.g., Alul et al., Nucleic Acids Research, Vol. 19, 1527 (1991)), TentaGel support-aminopolyethylene glycol-derivatized support (see, e.g., Wright et al., Tetrahedron Letters, Vol. 34, 3373 (1993)), and a Poros-polystyrene/divinylbenzene copolymer.
As a “linker,” it is possible to use a known linker which is commonly used to link a nucleic acid or a morpholino nucleic acid derivative, and examples include 3-aminopropyl, succinyl, 2,2′-diethanol sulfonyl, and a long-chain alkylamino (LCAA).
This step may be accomplished by treating compound (II) with an acid.
Examples of an “acid” available for use in this step include trifluoroacetic acid, dichloroacetic acid or trichloroacetic acid. The amount of an acid to be used is, for example, reasonably in the range of 0.1 molar equivalents to 1000 molar equivalents, preferably in the range of 1 molar equivalent to 100 molar equivalents, relative to 1 mole of compound (II).
Moreover, it is possible to use an organic amine together with the above acid. Any organic amine may be used for this purpose, and examples include triethylamine. The amount of an organic amine to be used is, for example, reasonably in the range of 0.01 molar equivalents to 10 molar equivalents, preferably in the range of 0.1 molar equivalents to 2 molar equivalents, relative to 1 mole of the acid.
In a case where an acid and an organic amine are used as a salt or mixture in this step, examples include a salt or mixture of trifluoroacetic acid and triethylamine, more specifically a mixture containing 2 equivalents of trifluoroacetic acid and 1 equivalent of triethylamine.
An acid available for use in this step may be used by being diluted with an appropriate solvent to give a concentration in the range of 0.1% to 30%. Any solvent may be used for this purpose as long as it is inert to the reaction, and examples include dichloromethane, acetonitrile, alcohols (e.g., ethanol, isopropanol, trifluoroethanol), water, or mixtures thereof.
The reaction temperature in the above reaction is, for example, preferably in the range of 10° C. to 50° C., more preferably in the range of 20° C. to 40° C., and even more preferably in the range of 25° C. to 35° C.
The reaction time will vary depending on the type of acid to be used and/or the reaction temperature, but it is generally reasonably in the range of 0.1 minutes to 24 hours, and preferably in the range of 1 minute to 5 hours.
Moreover, after completion of this step, a base may optionally be added to neutralize the acid remaining in the system. Any “base” may be used for this purpose and examples include diisopropylethylamine. Such a base may be used by being diluted with an appropriate solvent to give a concentration in the range of 0.1% (v/v) to 30% (v/v).
Any solvent may be used in this step as long as it is inert to the reaction, and examples include dichloromethane, acetonitrile, alcohols (e.g., ethanol, isopropanol, trifluoroethanol), water, or mixtures thereof. The reaction temperature is, for example, preferably in the range of 10° C. to 50° C., more preferably in the range of 20° C. to 40° C., and even more preferably in the range of 25° C. to 35° C.
The reaction time will vary depending on the type of base to be used and/or the reaction temperature, but it is generally reasonably in the range of 0.1 minutes to 24 hours, and preferably in the range of 1 minute to 5 hours.
It should be noted that compound (II) in which n =1 and L is group (IV), i.e., a compound represented by the following general formula (IIa) (hereinafter referred to as compound (IIa)) may be prepared in accordance with the following procedures:
[wherein B^P, T, Linker and Solid carrier are the same as defined above].
Step 1:
This is a step where a compound represented by the following general formula (V) is treated with an acylating agent to prepare a compound represented by the following general formula (VI) (hereinafter referred to as compound (VI)):
[wherein B^P, T and Linker are the same as defined above; and
R⁴represents a hydroxyl group, halogen, a carboxyl group or amino].
This step may be accomplished starting from compound (V) by any known reaction for linker introduction.
In particular, a compound represented by the following general formula (VIa) may be prepared by any process known as esterification reaction with the use of compound (V) and succinic anhydride:
[wherein B^Pand T are the same as defined above].
Step 2:
This is a step where compound (VI) is reacted with a solid carrier by being treated with a condensing agent or the like to prepare compound (IIa):
[wherein B^P, R⁴, T, Linker and Solid carrier are the same as defined above].
This step may be accomplished by any process known as condensation reaction with the use of compound (VI) and a solid carrier.
Compound (II) in which n=2 to 99 (preferably any an integer in the range of 13 to 29, 14 to 28, 15 to 27, 16 to 26, or 17 to 25) and L is group (IV), i.e., a compound represented by the following general formula (IIa2) may be prepared starting from compound (IIa) by repeating desired times Steps A and B of the process for PMO preparation disclosed herein:
[wherein B^P, R², R³, T, Linker and Solid carrier are the same as defined above; and
n′ represents 1 to 98 (in particular embodiments, n′ represents 1 to 28, 1 to 27, 1 to 26, 1 to 25, or 1 to 24)].
(2) Step B:
This is a step where compound (III) is treated with a morpholino monomer compound in the presence of a base to prepare a compound represented by the following general formula (VII) (hereinafter referred to as compound (VII)):
[wherein each B^P, L, n, R², R³and T are the same as defined above].
This step may be accomplished by treating compound (III) with a morpholino monomer compound in the presence of a base.
Such a morpholino monomer compound may be exemplified by a compound represented by the following general formula (VIII):
[wherein B^P, R², R³and T are the same as defined above].
Examples of a “base” available for use in this step include diisopropylethylamine, triethylamine or N-ethylmorpholine. The amount of a base to be used is, for example, reasonably in the range of 1 molar equivalent to 1000 molar equivalents, preferably in the range of 10 molar equivalents to 100 molar equivalents, relative to 1 mole of compound (III).
Such a morpholino monomer compound and a base available for use in this step may be used by being diluted with an appropriate solvent to give a concentration of 0.1% to 30%. Any solvent may be used for this purpose as long as it is inert to the reaction, and examples include N,N-dimethylimidazolidone, N-methylpiperidone, DMF, dichloromethane, acetonitrile, tetrahydrofuran, or mixtures thereof.
The reaction temperature is, for example, preferably in the range of 0° C. to 100° C., and more preferably in the range of 10° C. to 50° C.
The reaction time will vary depending on the type of base to be used and/or the reaction temperature, but it is generally reasonably in the range of 1 minute to 48 hours, and preferably in the range of 30 minutes to 24 hours.
Moreover, after completion of this step, an acylating agent may optionally be added. Examples of an “acylating agent” include acetic anhydride, acetic acid chloride and phenoxyacetic anhydride. Such an acylating agent may be used by being diluted with an appropriate solvent to give a concentration in the range of 0.1% to 30%, by way of example. Any solvent may be used for this purpose as long as it is inert to the reaction, and examples include dichloromethane, acetonitrile, tetrahydrofuran, alcohols (e.g., ethanol, isopropanol, trifluoroethanol), water, or mixtures thereof.
If necessary, it is possible to use a base (e.g., pyridine, lutidine, collidine, triethylamine, diisopropylethylamine, N-ethylmorpholine) together with an acylating agent. The amount of an acylating agent to be used is preferably in the range of 0.1 molar equivalents to 10000 molar equivalents, and more preferably in the range of 1 molar equivalent to 1000 molar equivalents. The amount of a base to be used is, for example, reasonably in the range of 0.1 molar equivalents to 100 molar equivalents, preferably in the range of 1 molar equivalent to 10 molar equivalents, relative to 1 mole of an acylating agent.
The reaction temperature in this reaction is preferably in the range of 10° C. to 50° C., more preferably in the range of 10° C. to 50° C., even more preferably in the range of 20° C. to 40° C., and still even more preferably in the range of 25° C. to 35° C. The reaction time will vary, e.g., depending on the type of acylating agent to be used and/or the reaction temperature, but it is generally reasonably in the range of 0.1 minutes to 24 hours, and preferably in the range of 1 minute to 5 hours.
(3) Step C:
This is a step where a deprotecting agent is used to remove the protecting groups from compound (VII) prepared in Step B, thereby preparing a compound represented by general formula (IX):
[wherein Base, B^P, L, n, R², R³and T are the same as defined above].
This step may be accomplished by treating compound (VII) with a deprotecting agent.
Examples of a “deprotecting agent” include concentrated aqueous ammonia and methylamine. Such a “deprotecting agent” available for use in this step may be used by being diluted with water, methanol, ethanol, isopropyl alcohol, acetonitrile, tetrahydrofuran, DMF, N,N-dimethylimidazolidinone, N-methylpiperidone, or a mixed solvent thereof. Among them, preferred is ethanol. The amount of a deprotecting agent to be used is, for example, reasonably in the range of 1 molar equivalent to 100000 molar equivalents, preferably in the range of 10 molar equivalents to 1000 molar equivalents, relative to 1 mole of compound (VII), by way of example.
The reaction temperature is, for example, reasonably in the range of 15° C. to 75° C., preferably in the range of 40° C. to 70° C., and more preferably in the range of 50° C. to 60° C. The reaction time for deprotection will vary depending on the type of compound (VII) and/or the reaction temperature, etc., but it is reasonably in the range of 10 minutes to 30 hours, preferably in the range of 30 minutes to 24 hours, and more preferably in the range of 5 hours to 20 hours.
(4) Step D:
This is a step where compound (LX) prepared in Step C is treated with an acid to prepare PMO (I):
[wherein Base, n, R², R³and T are the same as defined above].
This step may be accomplished by adding an acid to compound (IX).
Examples of an “acid” available for use in this step include trichloroacetic acid, dichloroacetic acid, acetic acid, phosphoric acid and hydrochloric acid, etc. As to the amount of an acid to be used, it is reasonable to use the acid in an amount to give a solution pH, for example, in the range of 0.1 to 4.0, more preferably in the range of 1.0 to 3.0. Any solvent may be used in this step as long as it is inert to the reaction, and examples include acetonitrile, water, or mixed solvents thereof.
The reaction temperature is preferably in the range of 10° C. to 50° C., more preferably in the range of 20° C. to 40° C., and even more preferably in the range of 25° C. to 35° C. The reaction time for deprotection will vary depending on the type of compound (IX) and/or the reaction temperature, etc., but it is reasonably in the range of 0.1 minutes to 5 hours, preferably in the range of 1 minute to 1 hour, and more preferably in the range of 1 minute to 30 minutes.
PMO (I) may be obtained from the reaction mixture obtained in this step by commonly used separation and purification means including extraction, concentration, neutralization, filtration, centrifugation, recrystallization, C₈to C₁₈reversed-phase column chromatography, cation exchange column chromatography, anion exchange column chromatography, gel filtration column chromatography, high performance liquid chromatography, dialysis, ultrafiltration and other means, which may be used either alone or in combination, whereby desired PMO (I) can be isolated and purified (see, e.g., WO1991/09033).
In the case of using reversed-phase chromatography for purification of PMO (I), a mixed solution of 20 mM triethylamine/acetate buffer and acetonitrile may be used as an elution solvent, by way of example.
Likewise, in the case of using ion exchange chromatography for purification of PMO (I), a mixed solution of 1 M aqueous sodium chloride and 10 mM aqueous sodium hydroxide may be used, by way of example.
The peptide nucleic acid oligomer is an antisense oligomer according to the present invention, whose constituent unit is a group represented by the following general formula:
(wherein Base is the same as defined above).
Peptide nucleic acids may be prepared, for example, in accordance with the documents listed below.

1) P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt, Science, 254, 1497 (1991)
2) M. Egholm, O. Buchardt, P. E. Nielsen, R. H. Berg, Jacs., 114, 1895 (1992)
3) K. L. Dueholm, M. Egholm, C. Behrens, L. Christensen, H. F. Hansen, T. Vulpius, K. H. Petersen, R. H. Berg, P. E. Nielsen, O. Buchardt, J. Org. Chem., 59, 5767 (1994)
4) L. Christensen, R. Fitzpatrick, B. Gildea, K. H. Petersen, H. F. Hansen, T. Koch, M. Egholm, O. Buchardt, P. E. Nielsen, J. Coull, R. H. Berg, J. Pept. Sci., 1, 175 (1995)
5) T. Koch, H. F. Hansen, P. Andersen, T. Larsen, H. G. Batz, K. Otteson, H. Orum, J. Pept. Res., 49, 80 (1997)

Moreover, the antisense oligomer of the present invention may be configured such that its 5′-terminal end is any one of the groups represented by chemical formulae (1) to (3) shown below, with (3) —OH being preferred.
2. Pharmaceutical Composition
In a preferred embodiment, the antisense oligomer of the present invention allows inhibition of myostatin at the mRNA level through induction of exon skipping or mRNA degradation. Thus, an amyotrophic disease or a muscle wasting disease can be prevented or treated when the antisense oligomer of the present invention according to this preferred embodiment, a pharmaceutically acceptable salt or hydrate thereof is administered to a subject in need of prevention or treatment of an amyotrophic disease or a muscle wasting disease.
In some embodiments of the present invention, there is provided a pharmaceutical composition comprising the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient (hereinafter referred to as “the pharmaceutical composition of the present invention”). The pharmaceutical composition of the present invention is preferably provided for use in the treatment of a metabolic disorder (e.g., obesity, metabolic syndrome, diabetes), an amyotrophic disease or a muscle wasting disease. Examples of an amyotrophic disease or a muscle wasting disease include myogenic amyotrophy (e.g., muscular dystrophy (e.g., Duchenne muscular dystrophy, Fukuyama muscular dystrophy, myotonic dystrophy), congenital myopathy, inclusion body myositis), neurogenic amyotrophy (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy), disuse amyotrophy (e.g., apoplexy-induced disuse syndrome), muscle wasting diseases (e.g., cancer cachexia, sepsis-related amyotrophy), various types of sarcopenia including age-related skeletal muscle loss (age-related sarcopenia), etc., with muscular dystrophy being preferred.
In some other embodiments of the present invention, there is provided a method for prevention or treatment of an amyotrophic disease or a muscle wasting disease, which comprises administering a subject in need of prevention or treatment of an amyotrophic disease or a muscle wasting disease with a therapeutically effective amount of the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof. In this method, the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof may be administered to the subject in the form of the pharmaceutical composition of the present invention.
In the context of the present invention, the term “subject” is intended to mean a human subject or a non-human warm-blooded animal, as exemplified by birds and non-human mammals (e.g., cow, monkey, cat, mouse, rat, guinea pig, hamster, pig, dog, rabbit, sheep, horse). The “subject” is preferably a human subject.
In some yet other embodiments of the present invention, there is provided use of the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a pharmaceutical composition for treatment of an amyotrophic disease or a muscle wasting disease.
In some yet other embodiments of the present invention, there is provided the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof for use in the treatment of an amyotrophic disease or a muscle wasting disease.
Examples of a pharmaceutically acceptable salt of the antisense oligomer of the present invention contained in the pharmaceutical composition of the present invention include alkali metal salts (e.g., sodium salt, potassium salt, lithium salt); alkaline earth metal salts (e.g., calcium salt, magnesium salt); metal salts (e.g., aluminum salt, iron salt, zinc salt, copper salt, nickel salt, cobalt salt); ammonium salt; organic amine salts (e.g., t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N′-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzyl-phenethylamine salt, piperazine salt, tetramethylammonium salt, tris(hydroxymethyl)aminomethane salt); hydrohalic acid salts (e.g., hydrofluoride salt, hydrochloride salt, hydrobromide salt, hydroiodide salt); inorganic acid salts (i.e., nitrate salt, perchlorate salt, sulfate salt, phosphate salt); lower alkanesulfonic acid salts (e.g., methanesulfonate salt, trifluoromethanesulfonate salt, ethanesulfonate salt); arylsulfonic acid salts (e.g., benzenesulfonate salt, p-toluenesulfonate salt); organic acid salts (e.g., acetate salt, malate salt, fumarate salt, succinate salt, citrate salt, tartrate salt, oxalate salt, maleate salt); amino acid salts (e.g., glycine salt, lysine salt, arginine salt, ornithine salt, glutamate salt, aspartate salt), etc. These salts may be prepared in any known manner.
The antisense oligomer of the present invention contained in the pharmaceutical composition of the present invention may be in the form of a hydrate thereof. Such a hydrate may be prepared in any known manner.
The pharmaceutical composition of the present invention may be administered in any pharmaceutically acceptable mode, which may be selected as appropriate for the intended therapeutic method. However, in terms of easy delivery to muscle tissue, preferred are intravenous administration, intraarterial administration, intramuscular administration, subcutaneous administration, oral administration, interstitial administration, percutaneous administration and so on. Moreover, the composition of the present invention may be in any dosage form, and examples include various types of injections, oral formulations, drops, inhalants, ointments, lotions, etc.
The pharmaceutical composition of the present invention comprises a carrier which promotes the delivery of the oligomer to muscle tissue. Such a carrier is not limited in any way as long as it is pharmaceutically acceptable, and examples include cationic carriers (e.g., cationic liposomes, cationic polymers) or viral envelope-based carriers. Examples of cationic liposomes include liposomes formed from 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol and a phospholipid as essential constituent members (hereinafter referred to as “liposome A”), Oligofectamine® (Invitrogen), Lipofectin® (Invitrogen), Lipofeetamine® (Invitrogen), Lipofectamine 2000® (Invitrogen), DMRIE-C® (Invitrogen), GeneSilencer® (Gene Therapy Systems), TransMessenger® (QIAGEN), TransIT TKO® (Mirus) and Nucleofector II (Lonza). Among them, preferred is liposome A. Examples of cationic polymers include JetSI® (Qbiogene) and Jet-PEI® (polyethyleneimine, Qbiogene). Examples of viral envelope-based carriers include GenomeOne® (HVJ-E liposomes, Ishihara Sangyo Kaisha, Ltd., Japan). Alternatively, it is also possible to use the pharmaceutical device shown in Japanese Patent No. 2924179 or the cationic carriers shown in JP WO2006/129594 and JP WO2008/096690.
For more details, reference may be made to U.S. Pat. Nos. 4,235,871 and 4,737,323, WO96/14057, “New RRC, Liposomes: A practical approach, IRL Press, Oxford (1990) pages 33-104,” etc.
The concentration of the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof contained in the pharmaceutical composition of the present invention will vary, e.g., depending on the type of carrier, but it is reasonably in the range of 0.1 nM to 100 μM, and preferably in the range of 100 nM to 10 μM. Likewise, the weight ratio of the carrier to the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof contained in the pharmaceutical composition of the present invention (i.e., the carrier/antisense oligomer or pharmaceutically acceptable salt or hydrate thereof ratio) will vary, e.g., depending on the properties of the oligomer and the type of the carrier, but it is reasonably in the range of 0.1 to 100, and preferably in the range of 0.1 to 10.
The pharmaceutical composition of the present invention may optionally comprise a pharmaceutically acceptable additive, in addition to the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof and a carrier as described above. Examples of such an additive include an emulsifier aid (e.g., a fatty acid containing 6 to 22 carbon atoms or a pharmaceutically acceptable salt thereof, albumin, dextran), a stabilizing agent (e.g., cholesterol, phosphatidic acid), an isotonizing agent (e.g., sodium chloride, glucose, maltose, lactose, sucrose, trehalose), and a pH adjuster (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, triethanolamine). These additives may be used either alone or in combination. The content of the additive(s) in the pharmaceutical composition of the present invention is reasonably 90% by weight or less, preferably 70% by weight or less, and more preferably 50% by weight or less.
The pharmaceutical composition of the present invention may be prepared by adding the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof to a dispersion of a carrier, followed by adequate stirring. An additive(s) may be added at any appropriate stage, either before or after adding the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof. Any aqueous solvent may be used for adding the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof as long as it is pharmaceutically acceptable, and examples include injectable water, injectable distilled water, electrolytic solutions (e.g., physiological saline), and sugar solutions (e.g., glucose solution, maltose solution). Moreover, in this case, conditions including pH and temperature may be selected as appropriate by those skilled in the art.
The pharmaceutical composition of the present invention may be formulated into a solution or a lyophilized formulation thereof, by way of example. Such a lyophilized formulation may be prepared in a standard manner by freeze-drying the pharmaceutical composition of the present invention in a solution form. For example, the pharmaceutical composition of the present invention in a solution form may be sterilized as appropriate and then dispensed in given amounts into vial bottles, followed by preliminary freezing under conditions of about −40° C. to −20° C. for about 2 hours, primary drying at about 0° C. to 10° C. under reduced pressure and then secondary drying at about 15° C. to 25° C. under reduced pressure. Moreover, in most cases, the vials may be purged with a nitrogen gas and then capped, thereby giving a lyophilized formulation of the pharmaceutical composition of the present invention.
Such a lyophilized formulation of the pharmaceutical composition of the present invention may generally be used after being reconstituted by addition of any appropriate solution (i.e., a reconstituting solution). Examples of such a reconstituting solution include injectable water, physiological saline, and other commonly used infusion solutions. The volume of such a reconstituting solution will vary, e.g., depending on the intended use and is not limited in any way, but it is reasonably 0.5- to 2-fold greater than the solution volume before freeze-drying, or 500 mL or less.
The dose for administration of the pharmaceutical composition of the present invention is desirably adjusted in consideration of the type of the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof contained therein, the intended dosage form, the condition of a subject such as age and body weight, the route of administration, and the nature and severity of a disease. If the subject is a human subject, the daily dose for adults is generally in the range of 0.1 mg to 10 g/human, preferably in the range of 1 mg to 1 g/human, calculated as the amount of the antisense oligomer of the present invention or a pharmaceutically acceptable salt or hydrate thereof. This numerical range may vary depending on the type of disease to be targeted, the mode of administration, and/or the type of target molecule. Thus, a dose lower than this range may be sufficient in some cases, or conversely, a dose higher than this range should be required in some cases. Moreover, the pharmaceutical composition of the present invention may be administered once to several times a day or at intervals of one to several days.
In another embodiment, the pharmaceutical composition of the present invention may be a pharmaceutical composition comprising a vector capable of expressing the antisense oligonucleotide of the present invention and a carrier as described above. Such an expression vector may be capable of expressing a plurality of antisense oligonucleotides according to the present invention. Such a pharmaceutical composition may optionally comprise a pharmaceutically acceptable additive, as described above. The concentration of the expression vector contained in this pharmaceutical composition will vary, e.g., depending on the type of carrier, but it is reasonably in the range of 0.1 nM to 100 μM, and preferably in the range of 100 nM to 10 μM. The weight ratio of the carrier to the expression vector contained in this pharmaceutical composition (i.e., the carrier/expression vector ratio) will vary, e.g., depending on the properties of the expression vector and the type of the carrier, but it is reasonably in the range of 0.1 to 100, and preferably in the range of 0.1 to 10. Moreover, the content of the carrier contained in this pharmaceutical composition is the same as described above, and procedures for preparation are also the same as described above.
It should be noted that all publications cited herein, including prior art documents, patent gazettes and other patent documents, are incorporated herein by reference.
The present invention will be further described in more detail below by way of the following illustrative examples, although the present invention is not limited thereto.

EXAMPLES

The present invention will be further described in more detail below by way of the following illustrative examples and test examples, although the present invention is not limited thereto.

Reference Example 1

4-{[(2S,6R)-6-(5-Methyl-2,4-dioxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded on aminopolystyrene resin

Step 1: Preparation of 4-{[(2S,6R)-6-(5-methyl-2,4-dioxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid

Under an argon atmosphere, 1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-5-methylpyrimidine-2,4-dione (41.11 g) and 4-dimethylaminopyridine (4-DMAP) (15.58 g) were suspended in dichloromethane (850 mL), and succinic anhydride (12.76 g) was then added thereto, followed by stirring at room temperature for 3.5 hours. The reaction solution was extracted with dichloromethane and 1 M aqueous sodium dihydrogen phosphate. The resulting organic layer was washed sequentially with 1 M aqueous sodium dihydrogen phosphate and saturated aqueous sodium chloride. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure. To the resulting solid, dichloromethane (600 mL) was added to effect crystallization, followed by filtration. After additional dichloromethane (300 mL) was added, the crystals were stirred for 5 minutes, and then filtered and dried overnight under reduced pressure to obtain the desired product (50.2 g).

Step 2: Preparation of 4-{[(25,6R)-6-(5-methyl-2,4-dioxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy) -4-oxobutanoic acid loaded on aminopolystyrene resin

4-[(2S,6R)-6-(5-Methyl-2,4-dioxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid (50.2 g) was dissolved in pyridine (dehydrated) (600 mL), followed by addition of 4-DMAP (12.4 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (77.6 g). The aminopolystyrene resin Aminomethyl resin (a product of Watanabe Chemical Industries, Ltd., Japan, A00673, 200 to 400 mesh, 1 mmol/g, 1% DVB) (40.5 g) and triethylamine (69.6 mL) were then added to this mixture, followed by shaking at room temperature for 4 days. After the reaction, the resin was collected by filtration. The resulting resin was washed sequentially with pyridine, methanol and dichloromethane, and then dried under reduced pressure. To the resulting resin, tetrahydrofuran (dehydrated) (500 mL), acetic anhydride (104 mL) and 2,6-lutidine (128 mL) were added, followed by shaking at room temperature for 4 hours. The resin was collected by filtration, washed sequentially with pyridine, methanol and dichloromethane, and then dried under reduced pressure to obtain 59.0 g of the desired product.
To determine the loading amount of the desired product, the molar amount of trityl per gram of the resin was measured in a known mariner as UV absorbance at 409 nm. The loading amount on the resin was found to be 467.83 μmol/g.
Conditions for UV measurement
Instrument: U-2910 (Hitachi, Ltd., Japan)
Solvent: methanesulfonic acid
Wavelength: 409 nm
ε value: 45000

Reference Example 2

4-{[(2S,6R)-6-(4-Benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic Acid Loaded on Aminopolystyrene Resin

The same procedures as shown in Reference Example 1 were repeated to prepare the titled compound, except that 1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-5-methylpyrimidine-2,4-dione used in Step 1 of Reference Example 1 was replaced in this step with N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide.
To determine the loading amount of the desired product, the molar amount of trityl per gram of the resin was measured in a known manner as UV absorbance at 409 nm. The loading amount on the resin was found to be 460.28 μmol/g.

Reference Example 3

4-{[(2S,6R)-6-(6-Benzamidopurin-9-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded on aminopolystyrene resin

The same procedures as shown in Reference Example 1 were repeated to prepare the titled compound, except that 1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-5-methylpyrimidine-2,4-dione used in Step 1 of Reference Example 1 was replaced in this step with N-{9-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]purin-6-yl}benzamide.
To determine the loading amount of the desired product, the molar amount of trityl per gram of the resin was measured in a known manner as UV absorbance at 409 nm. The loading amount on the resin was found to be 425.13 μmol/g.

Reference Example 4

4-{{(2S,6R)-6-{6-(2-Cyanoethoxy)-2-[(2-phenoxyacetyl)amino]purin-9-yl}-4-tritylmorpholin-2-yl}methoxy}-4-oxobutanoic Acid Loaded on Aminopolystyrene Resin

The same procedures as shown in Reference Example 1 were repeated to prepare the titled compound, except that 1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-5-methylpyrimidine-2,4-dione used in Step 1 of Reference Example 1 was replaced in this step with N-{6-(2-cyanoethoxy)-9-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]purin-2-yl}-2-phenoxyacetamide.
To determine the loading amount of the desired product, the molar amount of trityl per gram of the resin was measured in a known manner as UV absorbance at 409 nm. The loading amount on the resin was found to be 341.09 μmol/g.
In accordance with the descriptions in Example 1 shown below or in accordance with the procedures described in PCT/JP2015/57180 using a nucleic acid synthesizer (AKTA Oligopilot 10 plus), PMO Nos. 1 to 191, 198, 199, 201 to 316, 321 to 323, 325 to 327 and 333 indicated in Tables 1 to 3 were synthesized (the 5′-terminal end is group (3)).

TABLE 1

			Molecular	Molecular
PMO			weight	weight	SEQ
No.	Sequence name	Nucleotide sequence (5′>3′)	(calculated)	(measured)	ID NO:

1	MSTN_H2_128-140_157-169	TTCATAGGTTTGACACAAACACTGTT	8590.98	8591.04	93

2	MSTN_H2_169-181_213-225	TGCCTGGGTTCATCTTGTACCGTCTT	8556.93	8556.73	94

3	MSTN_HM2_169-181_341-353	TGGGAAGGTTACACTTGTACCGTCTT	8638.98	8638.93	95

4	MSTN_HM2_169-181_353-365	TTCTCCTGGTCCTCTTGTACCGTCTT	8467.90	8467.22	96

5	MSTN_H2_12-24_128-140	CACAAACACTGTTCATCCACTTGCAT	8480.95	8480.44	97

6	MSTN_H2_42-54_128-140	CACAAACACTGTTTAAATTTAAAGAA	8601.01	8600.99	98

7	MSTN_HM2_52-64_128-140	CACAAACACTGTTATTTTAGAGCTAA	8583.99	8583.56	99

8	MSTN_HM2_169-181_201-213	TGTCAAGTTTCAGCTTGTACCGTCTT	8564.94	8564.73	100

9	MSTN_H2_22-34_128-140	CACAAACACTGTTTTGGGTTTTCCAT	8557.95	8557.82	101

10	MSTN_HM2_128-140_347-359	TGGTCCTGGGAAGCACAAACACTGTT	8641.99	8641.67	102

11	MSTN_H2_2-14_116-128	TGTAGGAGTCTCGCATTAGAAAATCA	8665.01	8665.04	103

12	MSTN_H2_32-44_128-140	CACAAACACTGTTGAAGCAACATTTG	8593.99	8593.64	104

13	MSTN_H2_12-24_116-128	TGTAGGAGTCTCGCATCCACTTGCAT	8583.96	8583.74	105

14	MSTN_HM2_177-189_331-343	ACAGCAAGATCATCAGTATACCTTGT	8584.98	8584.99	106

15	MSTN_HM2_177-189_351-363	CTCCTGGTCCTGGCAGTATACCTTGT	8550.94	8550.82	107

16	MSTN_H2_2-14_128-140	CACAAACACTGTTCATTAGAAAATCA	8561.99	8561.39	108

17	MSTN_H2_72-84_128-140	CACAAACACTGTTTTACTACTTTATT	8500.94	8500.36	109

18	MSTN_HM2_177-189_341-353	TGGGAAGGTTACACAGTATACCTTGT	8672.00	8672.41	110

19	MSTN_H2_62-74_128-140	CACAAACACTGTTATTGTATTGTATT	8580.97	8580.58	111

20	MSTN_H2_82-94_128-140	CACAAACACTGTTAGTTGGGCCTTTA	8591.97	8591.99	112

21	MSTN_H2_2-14_119-131	TGTTGTAGGAGTCCATTAGAAAATCA	8680.01	8681.03	113

22	MSTN_H2_2-14_122-134	CACTGTTGTAGGACATTAGAAAATCA	8649.01	8649.13	114

23	MSTN_H2_92-104_128-140	CACAAACACTGTTATATATCCATAGT	8543.97	8544.20	115

24	MSTN_H2_102-114_128-140	CACAAACACTGTTCGGGTCTCAAATA	8569.98	8570.28	116

25	MSTN_H2_7-19_116-128	TGTAGGAGTCTCGACTTGCATTAGAA	8672.00	8671.90	117

26	MSTN_H2_2-14_113-125	AGGAGTCTCGACGCATTAGAAAATCA	8659.02	8659.54	118

27	MSTN_H2_2-14_125-137	AAACACTGTTGTACATTAGAAAATCA	8617.01	8617.59	119

28	MSTN_H2_112-124_128-140	CACAAACACTGTTGGAGTCTCGACGG	8626.99	8627.55	120

29	MSTN_H2_32-44_178-190	CCAGTATACCTTGGAAGCAACATTTG	8600.98	8599.85	121

30	MSTN_H2_32-44_193-205	TTCAGAGATCGGAGAAGCAACATTTG	8690.02	8689.34	122

31	MSTN_H2_32-44_347-359	TGGTCCTGGGAAGGAAGCAACATTTG	8722.02	8722.45	123

32	MSTN_HM2_193-205_347-359	TGGTCCTGGGAAGTTCAGAGATCGGA	8738.02	8737.65	124

33	MSTN_H2_2-14_347-359	TGGTCCTGGGAAGCATTAGAAAATCA	8690.02	8689.78	125

34	MSTN_H2_32-44_116-128	TGTAGGAGTCTCGGAAGCAACATTTG	8697.01	8696.54	126

35	MSTN_H2_116-128_178-190	CCAGTATACCTTGTGTAGGAGTCTCG	8623.97	8623.93	127

36	MSTN_H2_4-16_116-128	TGTAGGAGTCTCGTGCATTAGAAAAT	8696.01	8695.71	128

37	MSTN_H2_9-21_116-128	TGTAGGAGTCTCGCCACTTGCATTAG	8623.97	8623.22	129

38	MSTN_H2_-4-9_116-128	TGTAGGAGTCTCGGAAAATCAGCTAT	8681.01	8681.53	130

39	MSTN_H2_-2-11_116-128	TGTAGGAGTCTCGTAGAAAATCAGCT	8681.01	8681.66	131

40	MSTN_H2_2-14_32-44	GAAGCAACATTTGCATTAGAAAATCA	8642.02	8642.96	132

41	MSTN_H2_2-14_178-190	CCAGTATACCTTGCATTAGAAAATCA	8568.98	8569.60	133

42	MSTN_H2_3-14_117-128	TGTAGGAGTCTCCATTAGAAAATC	7970.77	7971.87	134

43	MSTN_H2_2-14_193-205	TTCAGAGATCGGACATTAGAAAATCA	8658.02	8657.79	135

44	MSTN_H2_116-128_347-359	TGGTCCTGGGAAGTGTAGGAGTCTCG	8745.01	8744.89	136

45	MSTN_H2_116-128_193-205	TTCAGAGATCGGATGTAGGAGTCTCG	8713.01	8713.65	137

46	MSTN_H2_2-13_116-127	GTAGGAGTCTCGATTAGAAAATCA	8019.79	8019.95	138

47	MSTN_H2_2-13_117-128	TGTAGGAGTCTCATTAGAAAATCA	7994.78	7994.91	139

48	MSTN_H2_3-14_116-127	GTAGGAGTCTCGCATTAGAAAATC	7995.78	7995.99	140

49	MSTN_H2_2-14_102-114	CGGGTCTCAAATACATTAGAAAATCA	8618.01	8618.54	141

50	MSTN_H2_2-14_106-118	TCGACGGGTCTCACATTAGAAAATCA	8609.99	8610.74	142

51	MSTN_H2_2-14_110-122	AGTCTCGACGGGTCATTAGAAAATCA	8650.01	8650.84	143

52	MSTN_H2_106-118_128-140	CACAAACACTGTTTCGACGGGTCTCA	8561.97	8562.71	144

53	MSTN_H2_109-121_128-140	CACAAACACTGTTGTCTCGACGGGTC	8577.97	8578.09	145

54	MSTN_H2_-1-12_116-128	TGTAGGAGTCTCGTTAGAAAATCAGC	8681.01	8681.08	146

55	MSTN_H2_1-13_116-128	TGTAGGAGTCTCGATTAGAAAATCAG	8705.02	8704.93	147

56	MSTN_H2_1-14_116-127	GTAGGAGTCTCGCATTAGAAAATCAG	8690.02	8690.13	148

57	MSTN_H2_-1-14_116-126	TAGGAGTCTCGCATTAGAAAATCAGC	8650.01	8649.42	149

58	MSTN_H2_2-14_117-129	TTGTAGGAGTCTCCATTAGAAAATCA	8640.00	8639.61	150

59	MSTN_H2_2-14_118-130	GTTGTAGGAGTCTCATTAGAAAATCA	8680.01	8679.96	151

60	MSTN_H2_3-15_116-128	TGTAGGAGTCTCGGCATTAGAAAATC	8681.01	8680.78	152

61	MSTN_H2_2-14_114-126	TAGGAGTCTCGACCATTAGAAAATCA	8634.01	8633.96	153

62	MSTN_H2_2-14_115-127	GTAGGAGTCTCGACATTAGAAAATCA	8674.02	8673.75	154

63	MSTN_H2_3-15_115-127	GTAGGAGTCTCGAGCATTAGAAAATC	8690.02	8689.33	155

64	MSTN_H2_3-15_117-129	TTGTAGGAGTCTCGCATTAGAAAATC	8656.00	8655.37	156

65	MSTN_H2_116-128_213-225	TGCCTGGGTTCATTGTAGGAGTCTCG	8670.98	8670.44	157

66	MSTN_H2_116-128_268-280	TGTTTGAGCCAATTGTAGGAGTCTCG	8678.99	8679.10	158

67	MSTN_H2_1-13_115-127	GTAGGAGTCTCGAATTAGAAAATCAG	8714.03	8714.18	159

68	MSTN_H2_1-13_117-129	TTGTAGGAGTCTCATTAGAAAATCAG	8680.01	8679.50	160

69	MSTN_H2_2-13_116-128	TGTAGGAGTCTCGATTAGAAAATCA	8349.90	8349.01	161

70	MSTN_H2_3-14_116-128	TGTAGGAGTCTCGCATTAGAAAATC	8325.89	8324.88	162

71	MSTN_H2_2-14_116-127	GTAGGAGTCTCGCATTAGAAAATCA	8334.90	8333.29	163

72	MSTN_H2_2-14_117-128	TGTAGGAGTCTCCATTAGAAAATCA	8309.89	8310.03	164

73	MSTN_H2_117-128_192-203	CAGAGATCGGATTGTAGGAGTCTC	8027.78	8027.24	165

74	MSTN_H2_117-128_193-204	TCAGAGATCGGATGTAGGAGTCTC	8027.78	8027.42	166

75	MSTN_H2_117-128_194-205	TTCAGAGATCGGTGTAGGAGTCTC	8018.77	8018.26	167

76	MSTN_H2_114-126_194-205	TTCAGAGATCGGTAGGAGTCTCGAC	8342.89	8342.62	168

77	MSTN_H2_115-128_192-203	CAGAGATCGGATTGTAGGAGTCTCGA	8722.02	8722.80	169

78	MSTN_H2_114-126_193-204	TCAGAGATCGGATAGGAGTCTCGAC	8351.90	8352.40	170

79	MSTN_H2_117-128_192-205	TTCAGAGATCGGATTGTAGGAGTCTC	8688.00	8687.62	171

80	MSTN_H2_3-14_116-125	AGGAGTCTCGCATTAGAAAATC	7310.55	7310.13	172

81	MSTN_H2_3-15_115-125	AGGAGTCTCGAGCATTAGAAAATC	8004.79	8004.56	173

82	MSTN_H2_-1-11_116-127	GTAGGAGTCTCGTAGAAAATCAGC	8020.79	8020.35	174

83	MSTN_H2_-1-12_115-125	AGGAGTCTCGATTAGAAAATCAGC	8004.79	8005.06	175

84	MSTN_H2_3-15_116-127	GTAGGAGTCTCGGCATTAGAAAATC	8350.90	8351.16	176

85	MSTN_H2_-1-12_116-127	GTAGGAGTCTCGTTAGAAAATCAGC	8350.90	8350.46	177

86	MSTN_H2_117-125_211-225	TGCCTGGGTTCATGTAGGAGTCTC	7985.75	7986.39	178

87	MSTN_H2_117-127_216-228	CAGTGCCTGGGTTGTAGGAGTCTC	8010.76	8011.08	179

88	MSTN_H2_2-14_116-126	TAGGAGTCTCGCATTAGAAAATCA	7979.78	7979.75	180

89	MSTN_H2_-1-12_116-126	TAGGAGTCTCGTTAGAAAATCAGC	7995.78	7996.47	181

90	MSTN_H2_-1-14_116-126(-5A)	TAGGAGTCTCGCATTAGAAATCAGC	8310.89	8311.25	182

91	MSTN_H2_117-127_344-358	GGTCCTGGGAAGGTTGTAGGAGTCTC	8745.01	8745.96	183

92	MSTN_H2_4-14_116-126	TAGGAGTCTCGCATTAGAAAAT	7325.55	7325.56	184

93	MSTN_H2_3-14_116-126	TAGGAGTCTCGCATTAGAAAATC	7640.66	7640.90	185

94	MSTN_H2_3-15_116-126	TAGGAGTCTCGGCATTAGAAAATC	7995.78	7996.39	186

95	MSTN_H2_117-127_344-356	TCCTGGGAAGGTTGTAGGAGTCTC	8034.77	8035.29	187

96	MSTN_H2_114-125_194-205	TTCAGAGATCGGAGGAGTCTCGAC	8012.78	8012.48	188

97	MSTN_H2_114-125_129-140	CACAAACACTGTAGGAGTCTCGAC	7925.76	7925.65	189

98	MSTN_H2_115-126_129-140	CACAAACACTGTTAGGAGTCTCGA	7940.76	7940.82	190

99	MSTN_H2_117-126_129-140	CACAAACACTGTTAGGAGTCTC	7246.52	7246.96	191

100	MSTN_H2_117-127_130-140	CACAAACACTGGTAGGAGTCTC	7271.53	7272.21	192

101	MSTN_H2_117-127_129-140	CACAAACACTGTGTAGGAGTCTC	7601.64	7602.24	193

102	MSTN_H2_117-127_192-202	AGAGATCGGATGTAGGAGTCTC	7382.56	7382.52	194

103	MSTN_H2_117-127_195-205	TTCAGAGATCGGTAGGAGTCTC	7333.54	7333.88	195

104	MSTN_H2_117-128_213-225	TGCCTGGGTTCATTGTAGGAGTCTC	8315.86	8316.77	196

105	MSTN_H2_114-125_213-225	TGCCTGGGTTCATAGGAGTCTCGAC	8309.86	8310.88	197

106	MSTN_H2_114-125_345-356	TCCTGGGAAGGTAGGAGTCTCGAC	8028.78	8028.48	198

107	MSTN_H2_117-128_348-359	TGGTCCTGGGAATGTAGGAGTCTC	8034.77	8034.02	199

108	MSTN_H2_114-125_211-222	CTGGGTTCATGTAGGAGTCTCGAC	7994.76	7995.78	200

109	MSTN_H2_117-128_211-222	CTGGGTTCATGTTGTAGGAGTCTC	8000.75	7999.95	201

110	MSTN_H2_115-125_129-140	CACAAACACTGTAGGAGTCTCGA	7610.65	7609.85	202

111	MSTN_H2_117-125_129-140	CACAAACACTGTAGGAGTCTC	6916.41	6916.94	203

112	MSTN_H2_117-128_193-205	TTCAGAGATCGGATGTAGGAGTCTC	8357.89	8357.86	204

113	MSTN_H2-1-10_15-26	TCCATCCACTTGAGAAAATCAGC	7545.63	7545.89	205

114	MSTN_H2_117-128_213-223	CCTGGGTTCATTGTAGGAGTCTC	7630.63	7631.02	206

115	MSTN_H2_119-125_211-225	TGCCTGGGTTCATGTAGGAGTC	7340.53	7341.36	207

116	MSTN_H2_117-125_211-223	CCTGGGTTCATGTAGGAGTCTC	7300.52	7301.46	208

117	MSTN_H2_-1-10_115-125	AGGAGTCTCGAAGAAAATCAGC	7344.57	7346.16	209

118	MSTN_H2_-1-10_116-126	TAGGAGTCTCGAGAAAATCAGC	7335.56	7336.62	210

119	MSTN_H2_3-13_116-126	TAGGAGTCTCGATTAGAAAATC	7325.55	7326.53	211

120	MSTN_H2_117-128_210-221	TGGGTTCATGTCTGTAGGAGTCTC	8000.75	8000.51	212

121	MSTN_H2_117-128_212-223	CCTGGGTTCATGTGTAGGAGTCTC	7985.75	7985.16	213

122	MSTN_H2_117-128_211-221	TGGGTTCATGTTGTAGGAGTCTC	7685.64	7685.86	214

123	MSTN_H2_118-128_211-222	CTGGGTTCATGTTGTAGGAGTCT	7685.64	7686.62	215

124	MSTN_H2_117-128_212-222	CTGGGTTCATGTGTAGGAGTCTC	7670.64	7670.94	216

125	MSTN_H2_117-128_192-204	TCAGAGATCGGATTGTAGGAGTCTC	8357.89	8358.93	217

126	MSTN_H2_117-128_213-222	CTGGGTTCATTGTAGGAGTCTC	7315.52	7316.24	218

127	MSTN_H2_117-129_213-222	CTGGGTTCATTTGTAGGAGTCTC	7645.63	7646.63	219

128	MSTN_H2_117-126_211-222	CTGGGTTCATGTTAGGAGTCTC	7315.52	7316.36	220

129	MSTN_H2_114-125_210-221	TGGGTTCATGTCAGGAGTCTCGAC	7994.76	7994.90	221

130	MSTN_H2_117-128_191-202	AGAGATCGGATTTGTAGGAGTCTC	8042.78	8043.31	222

131	MSTN_HM2_118-127_130-140	CACAAACACTGGTAGGAGTCT	6956.43	6956.19	223

132	MSTN_H2_117-127_130-139	ACAAACACTGGTAGGAGTCTC	6956.43	6956.76	224

133	MSTN_H2_114-125_212-223	CCTGGGTTCATGAGGAGTCTCGAC	7979.75	7979.45	225

134	MSTN_H2_118-128_213-223	CCTGGGTTCATTGTAGGAGTCT	7315.52	7315.38	226

135	MSTN_H2_118-128_213-222	CTGGGTTCATTGTAGGAGTCT	7000.41	7000.35	227

136	MSTN_H2_119-128_213-223	CCTGGGTTCATTGTAGGAGTC	6985.41	6984.76	228

137	MSTN_H2_117-126_213-223	CCTGGGTTCATTAGGAGTCTC	6945.40	6945.37	229

138	MSTN_H2_117-125_211-222	CTGGGTTCATGTAGGAGTCTC	6985.41	6985.57	230

139	MSTN_H2_117-127_214-223	CCTGGGTTCAGTAGGAGTCTC	6970.41	6969.84	231

140	MSTN_H2_117-128_131-140	CACAAACACTTGTAGGAGTCTC	7246.52	7246.02	232

141	MSTN_H2_115-125_130-140	CACAAACACTGAGGAGTCTCGA	7280.54	7280.06	233

142	MSTN_HM2_119-129_194-206	TTTCAGAGATCGGTTGTAGGAGTC	8033.77	8033.86	234

143	MSTN_HM2_118-129_193-204	TCAGAGATCGGATTGTAGGAGTCT	8042.78	8043.06	235

144	MSTN_H2_114-124_130-140	CACAAACACTGGGAGTCTCGAC	7256.53	7256.65	236

145	MSTN_H2_114-125_211-221	TGGGTTCATGTAGGAGTCTCGAC	7679.65	7679.17	237

146	MSTN_H2_114-126_213-222	CTGGGTTCATTAGGAGTCTCGAC	7639.64	7640.01	238

147	MSTN_H2_117-128_195-206	TTTCAGAGATCGTGTAGGAGTCTC	7993.76	7994.63	239

148	MSTN_H2_117-128_211-223	CCTGGGTTCATGTTGTAGGAGTCTC	8315.86	8316.07	240

149	MSTN_H2_117-126_213-222	CTGGGTTCATTAGGAGTCTC	6630.29	6631.27	241

150	MSTN_HM2_119-129_193-205	TTCAGAGATCGGATTGTAGGAGTC	8042.78	8043.75	242

151	MSTN_H2_118-127_214-223	CCTGGGTTCAGTAGGAGTCT	6655.30	6654.87	243

152	MSTN_H2_117-126_214-223	CCTGGGTTCATAGGAGTCTC	6615.29	6615.00	244

153	MSTN_H2_117-127_215-223	CCTGGGTTCGTAGGAGTCTC	6631.29	6631.07	245

154	MSTN_H2_114-124_214-223	CCTGGGTTCAGGAGTCTCGAC	6955.40	6955.05	246

155	MSTN_H2_115-125_214-223	CCTGGGTTCAAGGAGTCTCGA	6979.42	6979.46	247

156	MSTN_H2_118-128_214-223	CCTGGGTTCATGTAGGAGTCT	6985.41	6985.70	248

157	MSTN_HM2_118-129_192-203	CAGAGATCGGATTTGTAGGAGTCT	8042.78	8042.98	249

158	MSTN_HM2_118-129_194-205	TTCAGAGATCGGTTGTAGGAGTCT	8033.77	8033.36	250

159	MSTN_HM2_119-129_192-204	TCAGAGATCGGATTTGTAGGAGTC	8042.78	8043.12	251

160	MSTN_H2_117-129_213-223	CCTGGGTTCATTTGTAGGAGTCTC	7960.74	7960.09	252

161	MSTN_H2_117-127_188-198	ATCGGATTCCAGTAGGAGTCTC	7293.53	7294.09	253

162	MSTN_H2_117-127_198-208	AGTTTCAGAGAGTAGGAGTCTC	7357.55	7357.72	254

163	MSTN_H2_114-123_213-223	CCTGGGTTCATGAGTCTCGAC	6930.39	6930.41	255

164	MSTN_H2_119-129_213-222	CTGGGTTCATTTGTAGGAGTC	7000.41	7000.29	256

165	MSTN_HM2_119-129_191-203	CAGAGATCGGATTTTGTAGGAGTC	8042.78	8042.56	257

166	MSTN_H2_117-127_131-141	GCACAAACACTGTAGGAGTCTC	7271.53	7271.82	258

167	MSTN_H2_117-127_132-142	TGCACAAACACGTAGGAGTCTC	7271.53	7271.85	259

168	MSTN_H2_129-140_214-223	CCTGGGTTCACACAAACACTGT	7222.51	7222.91	260

169	MSTN_H2_129-140_212-223	CCTGGGTTCATGCACAAACACTGT	7907.74	7907.65	261

170	MSTN_HM2_129-140_192-203	CAGAGATCGGATCACAAACACTGT	7949.77	7949.90	262

171	MSTN_HM2_129-140_193-204	TCAGAGATCGGACACAAACACTGT	7949.77	7950.17	263

172	MSTN_H2_114-124_195-205	TTCAGAGATCGGGAGTCTCGAC	7318.54	7317.96	264

173	MSTN_H2_114-123_214-223	CCTGGGTTCAGAGTCTCGAC	6600.28	6600.76	265

174	MSTN_H2_117-127_180-190	CCAGTATACCTGTAGGAGTCTC	7253.51	7253.54	266

175	MSTN_H2_117-127_182-192	TTCCAGTATACGTAGGAGTCTC	7268.52	7268.89	267

176	MSTN_H2_193-204_212-223	CCTGGGTTCATGTCAGAGATCGGA	8003.77	8003.32	268

177	MSTN_H2_191-202_212-223	CCTGGGTTCATGAGAGATCGGATT	8018.77	8018.85	269

178	MSTN_H2_117-127_196-206	TTTCAGAGATCGTAGGAGTCTC	7308.53	7308.94	270

179	MSTN_H2_114-124_128-138	CAAACACTGTTGGAGTCTCGAC	7262.52	7262.78	271

180	MSTN_H2_114-124_129-139	ACAAACACTGTGGAGTCTCGAC	7271.53	7271.50	272

181	MSTN_H2_117-126_215-223	CCTGGGTTCTAGGAGTCTC	6276.17	6276.10	273

182	MSTN_H2_118-127_215-223	CCTGGGTTCGTAGGAGTCT	6316.18	6316.00	274

183	MSTN_H2_117-125_215-223	CCTGGGTTCAGGAGTCTC	5946.06	5946.39	275

184	MSTN_H2_118-126_215-223	CCTGGGTTCTAGGAGTCT	5961.06	5960.99	276

185	MSTN_H2_117-128_281-292	TTGGATTCAGGTTGTAGGAGTCTC	8024.76	8024.64	277

186	MSTN_H2_117-128_284-295	AAGTTGGATTCATGTAGGAGTCTC	8017.77	8017.74	278

187	MSTN_H2_117-128_139-150	TCAGGATTTGCATGTAGGAGTCTC	7993.76	7994.08	279

188	MSTN_H2_117-128_141-152	TCTCAGGATTTGTGTAGGAGTCTC	7984.75	7984.49	280

189	MSTN_H2_117-127_190-200	AGATCGGATTCGTAGGAGTCTC	7333.54	7333.23	281

190	MSTN_H2_117-127_193-203	CAGAGATCGGAGTAGGAGTCTC	7367.56	7368.05	282

191	MSTN_H2_117-127_194-204	TCAGAGATCGGGTAGGAGTCTC	7358.55	7358.58	283

192	MSTN_H2_179-190_212-223	CCTGGGTTCATGCCAGTATACCTT	7889.72	7889.74	284

193	MSTN_H2_181-192_212-223	CCTGGGTTCATGTTCCAGTATACC	7889.72	7890.21	285

194	MSTN_H2_212-223_267-278	TTTGAGCCAATTCCTGGGTTCATG	7944.74	7945.28	286

195	MSTN_H2_212-223_269-280	TGTTTGAGCCAACCTGGGTTCATG	7969.75	7969.96	287

196	MSTN_H2_212-223_345-356	TCCTGGGAAGGTCCTGGGTTCATG	8010.76	8010.35	288

197	MSTN_H2_212-223_348-359	TGGTCCTGGGAACCTGGGTTCATG	8010.76		289

198	MSTN_H2_117-126_196-205	TTCAGAGATCTAGGAGTCTC	6623.30	6622.99	371

199	MSTN_H2_117-126_195-204	TCAGAGATCGTAGGAGTCTC	6648.31	6648.32	372

200	MSTN_H2_117-126_194-203	CAGAGATCGGTAGGAGTCTC	6673.32	6673.28	373

201	MSTN_HM2_118-128_196-206	TTTCAGAGATCTGTAGGAGTCT	7323.53	7323.56	374

202	MSTN_HM2_118-128_195-205	TTCAGAGATCGTGTAGGAGTCT	7348.54	7348.26	375

203	MSTN_H2_114-124_196-206	TTTCAGAGATCGGAGTCTCGAC	7293.53	7293.71	376

204	MSTN_H2_117-128_195-204	TCAGAGATCGTGTAGGAGTCTC	7333.54	7333.02	377

TABLE 2

			Molecular	Molecular
PMO			weight	weight	SEQ
No.	Sequence name	Nucleotide sequence (5′>3′)	(calculated)	(measured)	ID NO:

205	MSTN_H2_21-45	AGAAGCAACATTTGGGTTTTCCATC	8276.87	8276.83	1

206	MSTN_H2_96-120	TCTCGACGGGTCTCAAATATATCCA	8221.85	8221.83	2

207	MSTN_H2_116-140	CACAAACACTGTTGTAGGAGTCTCG	8286.87	8286.48	3

208	MSTN_HM2_331-355	CCTGGGAAGGTTACAGCAAGATCAT	8335.90	8336.04	4

209	MSTN_H2_96-115	ACGGGTCTCAAATATATCCA	6576.30	6575.60	5

210	MSTN_H2_101-120	TCTCGACGGGTCTCAAATAT	6583.29	6583.07	6

211	MSTN_HM2_171-195	GGATTCCAGTATACCTTGTACCGTC	8228.84	8228.81	7

212	MSTN_HM2_166-190	CCAGTATACCTTGTACCGTCTTTCA	8163.82	8164.84	8

213	MSTN_HM2_336-360	CTGGTCCTGGGAAGGTTACAGCAAG	8367.90	8367.65	9

214	MSTN_HM2_341-365	TTCTCCTGGTCCTGGGAAGGTTACA	8284.85	8284.11	10

215	MSTN_HM2_136-160	TTGATGAGTCTCAGGATTTGCACAA	8316.88	8316.35	11

216	MSTN_H2_151-175	CCGTCTTTCATAGGTTTGATGAGTC	8274.85	8274.80	12

217	MSTN_H2_1-25	CCATCCACTTGCATTAGAAAATCAG	8214.86	8215.09	13

218	MSTN_HM2_346-370	CCATCTTCTCCTGGTCCTGGGAAGG	8245.84	8245.09	14

219	MSTN_H2_141-165	TAGGTTTGATGAGTCTCAGGATTTG	8378.88	8378.39	15

220	MSTN_H2_106-130	GTTGTAGGAGTCTCGACGGGTCTCA	8349.88	8349.83	16

221	MSTN_H2_106-125	AGGAGTCTCGACGGGTCTCA	6649.31	6649.01	17

222	MSTN_H2_116-135	ACACTGTTGTAGGAGTCTCG	6639.30	6639.41	18

223	MSTN_H2_98-117	CGACGGGTCTCAAATATATC	6592.30	6592.25	19

224	MSTN_H2_103-122	AGTCTCGACGGGTCTCAAAT	6608.30	6607.83	20

225	MSTN_H2_113-132	CTGTTGTAGGAGTCTCGACG	6655.30	6655.45	21

226	MSTN_H2_23-42	AGCAACATTTGGGTTTTCCA	6598.29	6598.57	22

227	MSTN_H2_116-137	AAACACTGTTGTAGGAGTCTCG	7317.54	7317.18	23

228	MSTN_HM2_121-145	ATTTGCACAAACACTGTTGTAGGAG	8325.89	8324.98	24

229	MSTN_HM2_121-140	CACAAACACTGTTGTAGGAG	6641.32	6641.73	25

230	MSTN_H2_111-135	ACACTGTTGTAGGAGTCTCGACGGG	8358.89	8358.77	26

231	MSTN_H2_111-130	GTTGTAGGAGTCTCGACGGG	6720.32	6720.08	27

232	MSTN_HM2_119-140	CACAAACACTGTTGTAGGAGTC	7286.54	7286.24	28

233	MSTN_H2_21-40	CAACATTTGGGTTTTCCATC	6549.27	6548.67	29

234	MSTN_H2_26-45	AGAAGCAACATTTGGGTTTT	6662.31	6662.77	30

235	MSTN_H2_-10-15	GCATTAGAAAATCAGCTATAAATGA	8326.91	8326.50	31

236	MSTN_H2_11-35	TTTGGGTTTTCCATCCACTTGCATT	8200.81	8200.79	32

237	MSTN_H2_6-30	GTTTTCCATCCACTTGCATTAGAAA	8211.84	8211.40	33

238	MSTN_H2_-5-20	CACTTGCATTAGAAAATCAGCTATA	8253.88	8253.71	34

239	MSTN_H2_101-125	AGGAGTCTCGACGGGTCTCAAATAT	8326.89	8326.20	35

240	MSTN_H2_112-136	AACACTGTTGTAGGAGTCTCGACGG	8342.89	8343.14	36

241	MSTN_H2_113-137	AAACACTGTTGTAGGAGTCTCGACG	8326.89	8327.41	37

242	MSTN_H2_115-139	ACAAACACTGTTGTAGGAGTCTCGA	8310.89	8310.85	38

243	MSTN_H2_114-138	CAAACACTGTTGTAGGAGTCTCGAC	8286.87	8286.68	39

244	MSTN_H2_117-141	GCACAAACACTGTTGTAGGAGTCTC	8286.87	8287.41	40

245	MSTN_HM2_118-142	TGCACAAACACTGTTGTAGGAGTCT	8301.88	8301.26	41

246	MSTN_HM2_119-143	TTGCACAAACACTGTTGTAGGAGTC	8301.88	8301.89	42

247	MSTN_HM2_120-144	TTTGCACAAACACTGTTGTAGGAGT	8316.88	8316.69	43

248	MSTN_H2_91-115	ACGGGTCTCAAATATATCCATAGTT	8260.87	8260,78	44

249	MSTN_H2_-3-22	TCCACTTGCATTAGAAAATCAGCTA	8229.86	8229.36	45

250	MSTN_HM2_191-215	CATGTCAAGTTTCAGAGATCGGATT	8316.88	8317.25	46

251	MSTN_H2_201-225	TGCCTGGGTTCATGTCAAGTTTCAG	8299.86	8299.68	47

252	MSTN_H2_211-235	CAAATACCAGTGCCTGGGTTCATGT	8277.86	8277.30	48

253	MSTN_H2_54-78	CTTTATTGTATTGTATTTTAGAGCT	8278.84	8278.45	49

254	MSTN_H2_-4-21	CCACTTGCATTAGAAAATCAGCTAT	8229.86	8229.68	50

255	MSTN_H2_-2-23	ATCCACTTGCATTAGAAAATCAGCT	8229.86	8229.37	51

256	MSTN_H2_-1-24	CATCCACTTGCATTAGAAAATCAGC	8214.86	8214.95	52

257	MSTN_H2_5-29	TTTTCCATCCACTTGCATTAGAAAA	8195.84	8194.80	53

258	MSTN_H2_2-26	TCCATCCACTTGCATTAGAAAATCA	8189.85	8189.90	54

259	MSTN_H2_3-27	TTCCATCCACTTGCATTAGAAAATC	8180.84	8181.54	55

260	MSTN_H2_4-28	TTTCCATCCACTTGCATTAGAAAAT	8195.84	8196.94	56

261	MSTN_H2_-7-18	CTTGCATTAGAAAATCAGCTATAAA	8277.89	8278.60	57

262	MSTN_H2_8-32	GGGYTTTCCATCCACTTGCATTAGA	8243.84	8244.65	58

263	MSTN_H2_117-138	CAAACACTGTTGTAGGAGTCTC	7277.53	7277.87	59

264	MSTN_HM2_118-139	ACAAACACTGTTGTAGGAGTCT	7301.54	7302.04	60

265	MSTN_H2_1-21	CCACTTGCATTAGAAAATCAG	6915.42	6915.68	61

266	MSTN_H2_9-29	TTTTCCATCCACTTGCATTAG	6839.36	6840.60	62

267	MSTN_H2_7-31	GGTTTTCCATCCACTTGCATTAGAA	8227.84	8226.95	63

268	MSTN_H2_5-25	CCATCCACTTGCATTAGAAAA	6875.40	6875.44	64

269	MSTN_H2_7-29	TTTTCCATCCACTTGCATTAGAA	7517.60	7517.22	65

270	MSTN_H2_117-140	CACAAACACTGTTGTAGGAGTCTC	7931.75	7931.52	66

271	MSTN_HM2_118-140	CACAAACACTGTTGTAGGAGTCT	7616.65	7616.24	67

272	MSTN_H2_1-23	ATCCACTTGCATTAGAAAATCAG	7584.65	7584.03	68

273	MSTN_H2_3-25	CCATCCACTTGCATTAGAAAATC	7520.62	7520.93	69

274	MSTN_H2_5-27	TTCCATCCACTTGCATTAGAAAA	7535.62	7536.03	70

275	MSTN_H2_93-117	CGACGGGTCTCAAATATATCCATAG	8270.87	8270.98	71

276	MSTN_H2_98-122	AGTCTCGACGGGTCTCAAATATATC	8261.86	8262.37	72

277	MSTN_H2_103-127	GTAGGAGTCTCGACGGGTCTCAAAT	8342.89	8343.04	73

278	MSTN_H2_108-132	CTGTTGTAGGAGTCTCGACGGGTCT	8340.87	8340.17	74

279	MSTN_H2_-1-25	CCATCCACTTGCATTAGAAAATCAGC	8529.97	8530.68	75

280	MSTN_H2_1-26	TCCATCCACTTGCATTAGAAAATCAG	8544.97	8545.57	76

281	MSTN_H2_116-139	ACAAACACTGTTGTAGGAGTCTCG	7971.77	7971.34	77

282	MSTN_HM2_120-141	GCACAAACACTGTTGTAGGAGT	7326.55	7326.14	78

283	MSTN_HM2_119-141	GCACAAACACTGTTGTAGGAGTC	7641.66	7641.12	79

284	MSTN_HM2_118-141	GCACAAACACTGTTGTAGGAGTCT	7971.77	7971.23	80

285	MSTN_H2_117-139	ACAAACACTGTTGTAGGAGTCTC	7616.65	7616.99	81

286	MSTN_HM2_120-140	CACAAACACTGTTGTAGGAGT	6971.43	6971.71	82

287	MSTN_H2_117-129	TTGTAGGAGTCTC	4290.49	4290.46	83

288	MSTN_H2_214-223	CCTGGGTTCA	3251.14	3251.29	84

289	MSTN_HM2_130-140	CACAAACACTG	3552.27	3552.07	85

290	MSTN_H2_117-127	GTAGGAGTCTC	3630.27	3630.01	86

291	MSTN_H2 117-128	TGTAGGAGTCTC	3960.38	3960.15	87

292	MSTN_H2_213-223	CCTGGGTTCAT	3581.25	3581.03	88

293	MSTN_HM2_193-205	TTCAGAGATCGGA	4308.51	4308.49	89

TABLE 3

			Molecular	Molecular
PMO			weight	weight	SEQ
No.	Sequence name	Nucleotide sequence (5′>3′)	(calculated)	(measured)	ID NO:

294	MSTN_M2_1-25	CCATCCGCTTGCATTAGAAAGTCAG	8246.86	8246.02	90

295	MSTN_M2_116-140	CACAAACACTGTTGTAGGAGTCTTG	8301.88	8302.03	91

296	MSTN_M2_21-45	AAAAGCAACATTTGGGCTTGCCATC	8270.87	8270.72	92

297	MSTN_M2_117-127_214-223	CCTGGGCTCAGTAGGAGTCTT	6970.41	6969.99	290

298	MSTN_M2_117-128_211-223	CCTGGGCTCATGTTGTAGGAGTCTT	8315.86	8315.79	291

299	MSTN_M2_1-14_116-127	GTAGGAGTCTTGCATTAGAAAGTCAG	8721.02	8721.53	292

300	MSTN_M2_117-129_213-223	CCTGGGCTCATTTGTAGGAGTCTT	7960.74	7960.75	293

301	MSTN_M2_114-125_212-223	CCTGGGCTCATGAGGAGTCTTGAC	7979.75	7979.86	294

302	MSTN_M2_117-127_130-140	CACAAACACTGGTAGGAGTCTT	7286.54	7286.69	295

303	MSTN_HM2_169-181_348-360	CTGGTCCTGGGAACTTGTACCGTCTT	8590.95	8591.36	296

304	MSTN_M2_117-128_213-223	CCTGGGCTCATTGTAGGAGTCTT	7630.63	7630.35	297

305	MSTN_M2_117-125_211-223	CCTGGGCTCATGTAGGAGTCTT	7300.52	7300.50	298

306	MSTN_M2_117-127_215-223	CCTGGGCTCGTAGGAGTCTT	6631.29	6631.39	299

307	MSTN_M2_118-128_213-223	CCTGGGCTCATTGTAGGAGTCT	7300.52	7300.55	300

308	MSTN_M2_117-128_214-225	TGCCTGGGCTCATGTAGGAGTCTT	7985.75	7985.85	301

309	MSTN_M2_117-128_271-282	GCTGTTTGAGCCTGTAGGAGTCTT	8000.75	8000.54	302

310	MSTN_M2_117-128_212-223	CCTGGGCTCATGTGTAGGAGTCTT	7985.75	7986.02	303

311	MSTN_M2_117-128_160-171	CTTTCATGGGTTTGTAGGAGTCTT	7990.74	7990.86	304

312	MSTN_M2_118-129_211-223	CCTGGGCTCATGTTTGTAGGAGTCT	8315.86	8316.08	305

313	MSTN_M2_117-128_212-224	GCCTGGGCTCATGTGTAGGAGTCTT	8340.87	8341.12	306

314	MSTN_M2_117-128_210-222	CTGGGCTCATGTCTGTAGGAGTCTT	8315.86	8316.11	307

315	MSTN_M2_116-127_211-223	CCTGGGCTCATGTGTAGGAGTCTTG	8340.87	8341.16	308

316	MSTN_HM2_118-128_180-191	TCCAGTATACCTTGTAGGAGTCT	7598.63	7598.40	309

317	MSTN_M2_117-128_156-167	CATGGGTTTGATTGTAGGAGTCTT	8039.76		310

318	MSTN_M2_117-128_278-289	GATTCAGGCTGTTGTAGGAGTCTT	8024.76	8026.40	311

319	MSTN_HM2_164-176_353-365	TTCTCCTGGTCCTACCGTCTTTCATG	8476.91	8477.91	312

320	MSTN_HM2_173-185_353-365	TTCTCCTGGTCCTATACCTTGTACCG	8485.92		313

321	MSTN_M2_90-102_117-128	TGTAGGAGTCTTATATCCACAGTTG	8307.87	8308.09	314

322	MSTN_HM2_119-130_192-203	CAGAGATCGGATGTTGTAGGAGTC	8067.79	8067.22	315

323	MSTN_HM2_118-129_191-202	AGAGATCGGATTTTGTAGGAGTCT	8057.78	8058.06	316

324	MSTN_M2_117-127_194-206	TTTCAGAGATCGGGTAGGAGTCTT	8033.77	8033.56	317

325	MSTN_HM2_118-128_194-206	TTTCAGAGATCGGTGTAGGAGTCT	8033.77	8033.04	318

326	MSTN_HM2_120-130_194-206	TTTCAGAGATCGGGTTGTAGGAGT	8073.78	8074.04	319

327	MSTN_HM2_119-129_190-202	AGAGATCGGATTCTTGTAGGAGTC	8042.78	8042.38	320

328	MSTN_M2_117-128_182-193	ATTCCAGTATACTGTAGGAGTCTT	7952.75	7952.88	321

329	MSTN_M2_117-128_180-191	TCCAGTATACCTTGTAGGAGTCTT	7928.74	7929.27	322

330	MSTN_M2_117-128_192-205	TTCAGAGATCGGATTGTAGGAGTCTT	8703.00	8703.29	367

331	MSTN_HM2_169-181_358-370	CCATCTTCTCCTGCTTGTACCGTCTT	8436.90	8437.03	368

332	MSTN_M2_93-105_117-128	TGTAGGAGTCTTGATATATCCACAG	8316.88	8316.77	369

333	MSTN_M2_117-128_192-203	CAGAGATCGGATTGTAGGAGTCTT	8042.78	8043.05	370

Example 1

4-{[(2S,6R)-6-(5-Methyl-2,4-dioxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded on aminopolystyrene resin (Reference Example 1) or 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded on aminopolystyrene resin (Reference Example 2) or 4-{[(2S,6R)-6-(6-benzamidopurin-9-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded on aminopolystyrene resin (Reference Example 3) or 4-{{(2S,6R)-6-6-(2-cyanoethoxy)-2-[(2-phenoxyacetyl)amino]purin-9-yl}-4-tritylmorpholin-2-yl)methoxy}-4-oxobutanoic acid loaded on aminopolystyrene resin (Reference Example 4), each corresponding to the 5′-terminal base, was filled in an amount of 0.1 g into a reaction vessel equipped with a filter to initiate the following synthesis cycles using a peptide synthesizer (FOCUS). To give the nucleotide sequence of each compound indicated in Tables 1 to 4, a desired morpholino monomer compound was added in each coupling cycle (see Table 4 below).

TABLE 4

		Volume	Time	Number
Step	Reagent	(mL/run)	(min/run)	of runs

1	Deblocking solution	1.8 to 3	0.1 to 2	3 to 8
2	Neutralizing solution	2 to 10	1	3
3	Dichloromethane	2 to 10	—	5
4	Activator solution	1.8 to 3	—	1
5	Monomer solution	1 to 1.5	—	1
6	Activator solution	0.9 to 1.4	—	1
7	Coupling reaction with		120 to 180
	the reagents charged in
	Steps 5 and 6
8	Dichloromethane	2 to 10	—	5
9	Capping solution	2 to 3	2	2
10	Dichloromethane	2 to 10	—	5

It should be noted that the deblocking solution used was prepared by dissolving a mixture of trifluoroacetic acid (2 equivalents) and triethylamine (1 equivalent) at a concentration of 3% (w/v) in a dichloromethane solution containing 1% (v/v) ethanol and 10% (v/v) 2,2,2-trifluoroethanol. The neutralizing solution used was prepared by dissolving N,N-diisopropylethylamine at a concentration of 5% (v/v) in a dichloromethane solution containing 25% (v/v) 2-propanol. The activator solution used was a 1,3-dimethyl-2-imidazolidinone solution containing 20% (v/v) N,N-diisopropylethylamine. The monomer solution used was prepared by dissolving a morpholino monomer compound at a concentration of 0.20 M in tetrahydrofuran. The capping solution used was prepared by dissolving acetic anhydride at 10% (v/v) and 2,6-lutidine at 15% (v/v) in dichloromethane.
The aminopolystyrene resin loaded with PMO synthesized as above was collected from the reaction vessel and dried at 30° C. for 2 hours or longer under reduced pressure. The dried PMO loaded on the aminopolystyrene resin was charged into a reaction vessel and 5 mL of 28% aqueous ammonia-ethanol (⅓) was added thereto, followed by standing at 55° C. for 16 hours. The aminopolystyrene resin was separated by filtration and washed with 3 mL of water-acetonitrile (1/1). After the resulting filtrate was mixed with ethanol (3 mL) and diethyl ether (35 mL), the mixture was centrifuged and then decanted to remove the supernatant, and the residue was dried under reduced pressure. The resulting residue was dissolved in 10 mL of a mixed solvent containing 20 mM aqueous ammonium acetate and acetonitrile (4/1), and then purified by reversed-phase HPLC. The conditions used are as indicated in Table 5 below.

TABLE 5

Column	XBridge	5 μm C18 (Waters,
	ϕ 19 × 50 mm, 1 CV = 14 mL)
Flow rate	10 mL/minute
Column	room temperature
temperature
Solution A	20 mM aqueous ammonium acetate
Solution B	CH₃CN
Gradient	(B) conc. 20% → 50%/10 CV

CV: column volume

The fractions were each analyzed to collect the desired product. The resulting solution was mixed with 0.1 M aqueous hydrochloric acid (4 mL) and allowed to stand for 2 hours. After the reaction, 1 M aqueous sodium hydroxide (0.4 mL) was added to neutralize the mixture, which was then filtered through a membrane filter (0.22 μm).
The resulting aqueous solution containing the desired product was made alkaline with 1 M aqueous sodium hydroxide (0.4 mL) and purified through an anion exchange resin column. The conditions used are as indicated in Table 6 below.

	TABLE 6

	Column	Source 15Q (GE Healthcare,
		ϕ16 × 97 mm, 1 CV = 19.5 mL)
	Flow rate	10 mL/minute
	Column	room temperature
	temperature
	Solution A
	10 mM aqueous sodium hydroxide
	Solution B
	10 mM aqueous sodium hydroxide,
		1M aqueous sodium chloride
	Gradient	(B) conc. 5% → 50%/20 CV

The fractions were each analyzed (by HPLC) to obtain the desired product as an aqueous solution. The resulting aqueous solution was neutralized with 0.1 M phosphate buffer (pH 6.0) and then desalted by reversed-phase HPLC under the conditions shown in Table 7 below.

	TABLE 7

	Column	YMC GEL C4 HG 10 μm
		(YMC, ϕ10 × 35 mm, 1 CV = 2.7 mL)
	Flow rate	10 mL/minute
	Column	room temperature
	temperature
	Solution A	water
	Solution B	CH₃CN
	Gradient	(B) conc. 0% → 50%/10 CV

The desired product was collected and concentrated under reduced pressure. The resulting residue was dissolved in water and freeze-dried to obtain the desired compound as a white flocculent solid. The calculated and measured values of ESI-TOF-MS are shown in Tables 1 to 3.

Test Example 1

In Vitro Assay

Into 3×10⁵RD cells (human rhabdomyosarcoma cell line), the antisense oligomers shown in Table 1 or 3 were each transfected at 1, 3 or 10 μM through Nucleofector II (Lonza) using an Amaxa Cell Line Nucleofector Kit L. The program used was T-030.
After transfection, the cells were cultured for three nights at 37° C. under 5% CO₂conditions in 2 mL of Dulbecco's Modified Eagle's Medium (DMEM) (SIGMA; the same applies hereinafter) containing 10% fetal calf serum (FCS) (Invitrogen).
After the cells were washed once with PBS (Nissui Pharmaceutical Co., Ltd., Japan; the same applies hereinafter), 350 μL of Buffer RLT (QIAGEN) containing 1% 2-mercaptoethanol (Nacalai Tesque, Inc., Japan) was added to the cells, and the cells were lysed by being allowed to stand at room temperature for a few minutes. The cell lysate was collected into a QIAshredder homogenizer (QIAGEN) and centrifuged at 20,400×g for 2 minutes to prepare a homogenate. The total RNA was extracted in accordance with the protocol attached to an RNeasy Mini Kit (QIAGEN). The concentration of the extracted total RNA was measured with a NanoDrop ND-1000 spectrophotometer (LMS Co., Ltd., Japan).
The extracted total RNA (10 ng) was used as a template to perform One-Step RT-PCR with a QIAGEN OneStep RT-PCR Kit (QIAGEN). A reaction solution was prepared in accordance with the protocol attached to the kit. The thermal cycler used was TaKaRa PCR Thermal Cycler Dice Touch (Takara Bio Inc., Japan). The RT-PCR program used is as shown below.
50° C. for 30 minutes: reverse transcription reaction
95° C. for 15 minutes: polymerase activation, reverse transcriptase inactivation
[94° C. for 30 seconds; 61° C. for 30 seconds; 72° C. for 1 minute]×27 cycles: PCR
72° C. for 7 minutes: final elongation reaction
The nucleotide sequences of the forward and reverse primers used for RT-PCR are as shown below.

	Forward primer:
	(SEQ ID NO: 360)
	5′-TTCGTCTGGAAACAGCTCCT-3′

	Reverse primer:
	(SEQ ID NO: 361)
	5′-AGAGGGTAACGACAGCATCG-3′

The above PCR reaction product (1 μL) was analyzed using a Bioanalyzer (Agilent).
The polynucleotide level “A” in the PCR amplicon with exon 2 skipping and the polynucleotide level “B” in the wild-type PCR amplicon were measured. Based on these measured values of “A” and “B,” the skipping efficiency was determined according to the following equation.
Skipping efficiency (%)=A/(A+B)×100
Experimental Results
The results obtained are shown in FIGS. 1 to 14.
FIGS. 1 to 14 indicated that the antisense oligomer of the present invention effectively caused exon 2 skipping.

Test Example 2

In Vitro Assay

The same procedures as shown in Test Example 1 were repeated to conduct this experiment, except that 3 x 10⁵RD cells (human rhabdomyosarcoma cell line) were transfected with the oligomer of the present invention alone (PMO No. 100 (NMS-191), PMO No. 139 (NMS-233), PMO No. 79 (NMS-169) or PMO No. 114 (NMS-206)) or with either of the two unit oligomers constituting each oligomer or with a cocktail of the two unit oligomers constituting each oligomer through Nucleofector II (Lonza) using an Amaxa Cell Line Nucleofector Kit L. The pulse program used was T-030. Combinations of the sequences transfected are as shown below.

	TABLE 8

	Sequence	Transfection concentration

1	PMO No. 100 (NMS-191) alone	3 μm
	PMO No. 290 (NMS-258) alone,	3 μm
	which is a unit oligomer
	constituting PMO No. 100
	(NMS-191)
	PMO No. 289 (NMS-257) alone,	3 μm
	which is a unit oligomer
	constituting PMO No. 100
	(NMS-191)
	Cocktail of two unit oligomers	3 μm each
	constituting PMO No. 100
	(NMS-191) (i.e., PMO No. 290
	(NMS-258) and PMO No. 289
	(NMS-257))
2	PMO No. 139 (NMS-233) alone	1 μm
	PMO No. 290 (NMS-258) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 139
	(NMS-233)
	PMO No. 288 (NMS-237) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 139
	(NMS-233)
	Cocktail of two unit oligomers	1 μm each
	constituting PMO No. 139
	(NMS-233) (i.e., PMO No. 290
	(NMS-258) and PMO No. 288
	(NMS-237))
3	PMO No. 79 (NMS-169) alone	1 μm
	PMO No. 287 (NMS-236) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 79
	(NMS-169)
	PMO No. 293 (NMS-265) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 79
	(NMS-169)
	Cocktail of two unit oligomers	1 μm each
	constituting PMO No. 79 (NMS-169)
	(i.e., PMO No. 287 (NMS-236)
	and PMO No. 293 (NMS-265))
4	PMO No. 114 (NMS-206) alone	1 μm
	PMO No. 287 (NMS-236) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 114
	(NMS-206)
	PMO No. 288 (NMS-237) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 114
	(NMS-206)
	Cocktail of two unit oligomers	1 μm each
	constituting PMO No. 114
	(NMS-206) (i.e., PMO No. 287
	(NMS-236) and PMO No. 288
	(NMS-237))
5	PMO No. 114 (NMS-206) alone	1 μm
	PMO No. 291 (NMS-263) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 114
	(NMS-206)
	PMO No. 292 (NMS-264) alone,	1 μm
	which is a unit oligomer
	constituting PMO No. 114
	(NMS-206)
	Cocktail of two unit oligomers	1 μm each
	constituting PMO No. 114
	(NMS-206) (i.e., PMO No. 291
	(NMS-263) and PMO No. 292
	(NMS-264))

Experimental Results
The results obtained are shown in FIG. 15. This experiment indicated that when compared to a cocktail of two antisense nucleic acids targeting different sites in exon 2 (i.e., PMO No. 290 (NMS-258) and PMO No. 289 (NMS-257), PMO No. 290 (NMS-258) and PMO No. 288 (NMS-237), PMO No. 287 (NMS-236) and PMO No. 293 (NMS-265), PMO No. 287 (NMS-236) and PMO No. 288 (NMS-237), or PMO No. 291 (NMS-263) and PMO No. 292 (NMS-264)), the oligomers of the present invention, i.e., PMO No. 100 (NMS-191), PMO No. 139 (NMS-233), PMO No. 79 (NMS-169) and PMO No. 114 (NMS-206), in which the respective two antisense nucleic acids are connected together, caused exon 2 skipping with higher efficiency.

Claims

1.-22. (canceled)

23. Any one antisense oligomer selected from the group consisting of (A) to (H) shown below or a pharmaceutically acceptable salt or hydrate thereof:

(A) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 45 from the 5′-terminal end of exon 2 in the human myostatin gene;

(B) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 91 to 145 from the 5′-terminal end of exon 2 in the human myostatin gene;

(C) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene;

(D) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene;

(E) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the mouse myostatin gene;

(F) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 111 to 162 from the 5′-terminal end of exon 2 in the mouse myostatin gene;

(G) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 166 to 195 from the 5′-terminal end of exon 2 in the mouse myostatin gene; and

(H) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the mouse myostatin gene.

24. Any one antisense oligomer selected from the group consisting of (I) to (L) shown below or a pharmaceutically acceptable salt or hydrate thereof:

(I) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions −10 to 31 from the 5′-terminal end of exon 2 in the human myostatin gene;

(J) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 111 to 140 from the 5′-terminal end of exon 2 in the human myostatin gene, wherein the 3′-terminal base of the nucleotide sequence of 14 to 30 bases in length is a base located at position 140 from the 5′-terminal end of said exon 2;

(K) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 146 to 180 from the 5′-terminal end of exon 2 in the human myostatin gene; and

(L) an antisense oligomer consisting of a nucleotide sequence complementary to a nucleotide sequence of contiguous 14 to 30 bases in length selected from a nucleotide sequence located at positions 331 to 374 from the 5′-terminal end of exon 2 in the human myostatin gene.

25. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (A) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 13 (NMS-17), SEQ ID NO: 76 (NMS-138), SEQ ID NO: 68 (NMS-120), SEQ ID NO: 75 (NMS-137), SEQ ID NO: 51 (NMS-76), SEQ ID NO: 52 (NMS-79), SEQ ID NO: 54 (NMS-81), SEQ ID NO: 55 (NMS-82), SEQ ID NO: 56 (NMS-83), SEQ ID NO: 53 (NMS-80), SEQ ID NO: 33 (NMS-49), SEQ ID NO: 63 (NMS-114), SEQ ID NO: 69 (NMS-124), SEQ ID NO: 70 (NMS-125), SEQ ID NO: 61 (NMS-110), SEQ ID NO: 31 (NMS-46), SEQ ID NO: 34 (NMS-50), SEQ ID NO: 50 (NMS-75), SEQ ID NO: 45 (NMS-67) and SEQ ID NO: 64 (NMS-115).

26. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (B) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 3 (NMS-6), SEQ ID NO:

66 (NMS-118), SEQ ID NO: 67 (NMS-119), SEQ ID NO: 28 (NMS-33), SEQ ID NO: 72 (NMS-127), SEQ ID NO: 16 (NMS-20), SEQ ID NO: 82 (NMS-187) and SEQ ID NO: 25 (NMS-30).

27. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (C) consists of a nucleotide sequence shown in SEQ ID NO: 12 (NMS-16).

28. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (D) consists of a nucleotide sequence shown in SEQ ID NO: 4 (NMS-7).

29. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (E) consists of a nucleotide sequence shown in SEQ ID NO: 90 (NMS-51).

30. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (F) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 91 (NMS-52), SEQ ID NO: 28 (NMS-33) and SEQ ID NO: 25 (NMS-30), SEQ ID NO: 41 (NMS-61), SEQ ID NO: 24 (NMS-29), SEQ ID NO: 42 (NMS-62), SEQ ID NO: 43 (NMS-63), SEQ ID NO: 11 (NMS-15), SEQ ID NO: 67 (NMS-119), SEQ ID NO: 80 (NMS-161) and SEQ ID NO: 82 (NMS-187).

31. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (G) consists of a nucleotide sequence shown in SEQ ID NO: 7 (NMS-10).

32. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer (H) consists of any one nucleotide sequence selected from the group consisting of SEQ ID NO: 4 (NMS-7), SEQ ID NO:

9 (NMS-12), SEQ ID NO: 10 (NMS-14) and SEQ ID NO: 14 (NMS-18).

33. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof claim 23, wherein the antisense oligomer is an oligonucleotide.

34. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 33, wherein at least one sugar moiety and/or at least one phosphate bond moiety in nucleotides constituting the oligonucleotide is modified.

35. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 34, wherein the at least one sugar moiety in nucleotides constituting the oligonucleotide is a ribose in which the —OH group at the 2′-position is substituted with any group selected from the group consisting of OR, R, R′OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R represents alkyl or aryl, and R′ represents alkylene).

36. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 34, wherein the at least one phosphate bond moiety in nucleotides constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoroamidate bond and a boranophosphate bond.

37. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23, wherein the antisense oligomer is a morpholino oligomer.

38. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 37, wherein the morpholino oligomer is a phosphorodiamidate morpholino oligomer.

39. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 37, whose 5′-terminal end is any one of the groups represented by chemical formulae (1) to (3) shown below:

40. A pharmaceutical composition comprising the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23.

41. The pharmaceutical composition according to claim 40, which further comprises a pharmaceutically acceptable carrier.

42. The pharmaceutical composition according to claim 40 or 41 for use in the treatment of an amyotrophic disease or a muscle wasting disease.

43. The pharmaceutical composition according to claim 42 for use in the treatment of muscular dystrophy.

44. A method for prevention or treatment of an amyotrophic disease or a muscle wasting disease, which comprises administering a subject in need of prevention or treatment of an amyotrophic disease or a muscle wasting disease with a therapeutically effective amount of the antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 23.

45. The method according to claim 44, wherein the amyotrophic disease or muscle wasting disease is muscular dystrophy.

46. The method according to claim 44, wherein the subject is a human subject.

47-48. (canceled)